annual report innovate healthcarecover gudrun schindler know important people diabete able monitor blood glucose level easily reliably type diabete actively involved diabete project gambia africa running diabetes selfhelp group past year year gudrun accuchek system roche diabete management area roche strong focus research produce pioneer innovation help group global market leader key figure key figure millions chf roche group continue businessesa change change chf chf sale research development ebitdab operating profit exceptional item operating profit financial income net income exceptional itemsc net income epsdbefore exceptional item chf epsdin chf research development sale ebitda sale operating profit exceptional item sale effective tax rate net income sale roche group roche group december december net liquidity total asset equity minority interest debt equity ratioe debtequity ratiof continue business include pharmaceutical diagnostic business treasury corporate activity consumer health otc vitamin fine chemical report discontinue business ebitda earning exceptional item interest financial income tax depreciation amortisation include impairment correspond operate profit exceptional item depreciation amortisation include impairment net income exceptional item ep exceptional item calculate show eps earning share nonvoting equity security dilute equity ratio equity minority interest percentage total asset debtequity ratio debt percentage equity include minority interest local currency nonvoting equity security genussschein price performance chf roche nonvoting equity security adjust swiss market index rebase brief sale grow significantly ahead market net income double group sale continue business local currency high operating profit roche history net income double billion swiss franc substantial improvement equitytoasset ratio net liquidity board propose consecutive dividend increase swiss franc share nonvoting equity security pharmaceutical division gain additional market share operating profit margin significantly market leadership oncology strengthen innovative anticancer medicine avastin tarceva receive market approval filing submit bonivabonviva osteoporosis sixtyfour new molecular entity pipeline diagnostic sixth straight year market share gain significant improvement operating profit margin growth significantly market average key segment dna chipbase test introduce support personalise therapy outlook pharmaceutical diagnostic division expect continue market growth visit httpwwwrochecom additional information roche operate profit margin exceptional item annual report innovative solution span entire healthcare spectrum predisposition early detection prevention diagnosis therapy monitor roche mission improve people health quality life lead researchdriven healthcare company roche develop produce market inno vative highquality product service unmet medical need capability diagnostic pharmaceutical enable innovate entire health care spectrum identify disease susceptibilitie disease screening population risk prevention diagnosis therapy treatment monitor annual report table content annual report letter chairman predispositionamplichip cyp test roche group group result outlook strategy pharmaceutical result region therapeutic area early detectionamplicor hpv test research development pipeline diagnostic result regions business area research development key product launch schedule preventionpegasys board directors executive committee board directors executive committee corporate governance finance diagnosisserum work area roche group financial review roche group consolidated financial statement note roche group consolidated financial statement report group auditor multiyear overview supplementary net income therapymabtherarituxan ep information roche security roche holding ltd basel financial statement note financial statement appropriation available earning report statutory auditor monitoringaccuchek roche global market presence sustainability report publish asa companion volume annual report annual report letter chairman franz bhumerchairman chiefexecutive officer outstanding year companywe carethe group pharmaceutical diagnostic achieve case exceed business supply product span entire ambitious goal yearour operating profit healthcare spectrumfrom early detection highest roche historywe gain prevention disease diagnosis treatment marketing approval breakthrough anti business excellent strategic fit cancer medicinesand intensify focus play major role shape core capabilitiesthank strong oper future medicine contribute ate performance gain sale ofour sonalise therapyfor examplegiven treman consumer health business net income dous need new well medical solution double reach billion swiss franc explosive progress science technology annual general meeting ofshareholders board outlook continue growth good despite director propose dividend increase todays challenging marketplace swiss franc share nonvoting equity securityifapprovedthis group year roche division post eighteenth consecutive dividend increase sale growth significantly market average improve profitabilityas resultcom follow sale consumer health unit bin operating profit continue business today roche clearly position research exceptional item rise approximately drive company focus innovation health billion swiss franc annual report letter chairman reinforce leadership oncology expiry pharmaceutical industry rocephin gain market share major therapeutic major roche drug area ofinterestinclude virology transplan patent united states tationas resultroche move global successful move ranking eighth large pharma major research development project forward ceutical company diagnostic business expect add innova perform strongly sixth straight year tive medicine portfolio year ahead grow significantly fast market pharmaceutical diagnostic pipeline extend market leadership today rank good industrythank strong financial commitment importantly future division area invest billion swiss franc score major success bring innovative annually new product market advance project research development pipeline year roche receive prestigious prix galien tarcevawhich approve year united nobel prizefor pharmaceutical innovation state medicine class pioneer new hivaid medicine fuzeon show improve survival patient advanced cancer lung pancreasavastin roche genentech chugai medicine offer completely new therapeutic world leader biotechnologyand area approach colorectal cancerreceive mar intend strongerboth ket approval united states february research development production end ofthe year generate nearly mil year example lion swiss franc sale new invest billion swiss franc expand biopharmaceutical adopt quickly group biotech production capacity basel prescribersthe significance ofthese achievement switzerlandpenzberg germanyvacaville usa go far commercial impactfor utsunomiya japan fresh hope patient cancerwhich second lead cause ofdeath industri company afford high level expendi alise country ture project require commercial risk involve solid financial addition gain market approval footingour financial position improve substan anticancer medicine receive tially yearthank strong gross approval lymphoma treatment mabthera cash flow billion swiss franc rituxan hepatitis drug pegasys new indi core businessesgroup debt interest expense cation mean significantly large decline significantly net liquidity double number patient eligible treat billion swiss franc ratio ment important productsin diag equity total asset reach nostic division launch accuchek insulin pump stateoftheart device course solid financial benefit people live diabetesand sustainable business success second launch amplichip cyp test europe year yearend reporting include sus united states important step tainability report describe progress personalise medicinethis dna chipbase create value environment economy test mark begin new generation society respect business magazine diagnostic tool identify clinically relevant recently include time list genetic variation help improve treatment good company work united outcomes statesthis honour share european companiesand employee thank young product portfolio proud roche low exposure patent annual report letter chairman year steadily strengthen corporate governance roche bruno gehrig serve board independent lead director year annual general meetingand recent change struc ture corporate executive committee give broad leadership base establish clear deputising arrangement company today enjoy number ofsignificant competitive advantage equip continue successi wish thank youour share holdersfor confidence strategy roche management team like tothank employee valuable contribu tion make good year roche franz bhumer annual report medicine work differently sister sarah staehelin live family binningenswitzerlandmetabolise certain medication moreslowly childrenthis mean normaldose child age toxic predisposition early detection prevention diagnosis therapy monitor annual report dna chip technology tremendous promise reason respond differently dose medicine lie gene expert estimate genetic factor account difference individual metabolise respond drug amplichip cyp test enable comprehensive analysis gene play key role metabolism widely prescribe drug dna chipbase test approve clinical diagnostic use test help predict basis patient genetic makeup metabolise certain medicine slowly normally quickly information assist doctor prescribe appropriate medication appropriate dose patient dna chip long earn place disease research amplichip cyp test signal start new era clinical diagnostic chipbase test help doctor tailor therapy patient individual genetic profile predisposition gene influence effectiveness certain drug contribute risk develop disease advance human genetic promise new insight link gene disease understand link great chance day able use genebase test well identify predisposition disease early knowl edge help doctor patient timely action delay possibly prevent onset disease annual report roche group group result beforeand diagnostic division ebitda margin advanced percentage point sale revenue group continue busi group net liquidity nearly double ness rise billion swiss franc billion swiss francsthank strong increase local currency swiss positive cash flow divisionsthe sale ofthe franc result exclude consumer health consumer health otc business conver otc business vitamin fine sion ofthe lyon ivnotesthe ratio ofequity chemical business sell total asset rise significantlyfrom roche divisionspharmaceutical diagnostic grow significantly fast global market sale ofthe otc business roche chugai prescription drug sale advance local result exceptional pretax gain totalling currency swiss franc positive billion swiss franc contribution growth come roche prescription subdivision local currency group complete major acquisition dur strategic alliance genentech ing yearpurchasing igen united states united state dollar chugai early total consideration billion japan japanese yenin diagnostic swiss franc division sale rise local currency swiss franc lead division diabetes care financial income show yearonyear molecular diagnostic immunochemistry busi improvement group recording net nesseswhich post growth significantly financial expense million swiss franc market average compare expense million swiss franc group debt reduce operating profit continue business billion swiss franc billion swiss substantially year advance franc result decrease interest expense local currency swiss franc nearly condition place balanced billion swiss franc exceptional item financial income conversion operate profit margin division redemption debt instrument yield excep increase sharply pharmaceutical tional pretax gain million swiss franc division operate profit margin rise include exceptional gain financial income centage point margin positive diagnostic division gain percentage point reach strong sale growth productivity net income increase billion swiss improvement gain realise dis franc billion swiss franc thank fur posal noncore product technologie ther improvement group operating result roche continue realign product portfolio gain sale otc business major contributor group improve conversion redemption debt instru profitabilitytogether factor ment set increase cost new product launch investment group pipeline expenditure inlicense agreement prod outlook uct technology exclude gain disposal product operate margin result pharmaceutical division improve significantly influence expiry ofthe patent rocephin cost product launch key thank strong operating performance ofthe market significant development activitiesas group continue businessesebitda overall outcome anticipate localcurrency business billion swiss franc sale growth world market oper ebitda margin thepharmaceutical divi ate profit margin exceptional item sion reach compare year broadly line annual report roche group roche diagnostic expect outgrow pharmaceutical diagnostic division world market term oflocalcurrency sale majority shareholding genentech division expect progress usa chugai japan backbone ofour goal ofan operating profit margin excep innovation network capability aug tional item ofaround mente technology collaboration constel lation alliance develop individual product addition roche expect balanced financial entire product portfolio decentralise income strategy enable combine maximum scope flexibilitywhile allow partner necessary entrepreneurial freedom strategy pharmaceutical group roche pharmaceutical discoversdevelopsmanu scientific advance demographic trend eco facture market clinically differentiate med nomic development reshape healthcare icine offer real add value exist treat healthcare industrythe explosion ofscientific ment effort focus address unmet knowledge lead discipline genetic inadequately meet medical need select genomic proteomic bioinformatics pro therapeutic area particularly develop vide completely new insight human biology medicine help extend length diseaseopening way new approach improve quality people liveswe aim diagnosis treatment good news aleader ofour area ofinter lack effective treatment ofthe dis ease afflict mankindto large extentof oncology good example ofthe strategic course coursedecision resource set aside pursue anticancer medicine infrastructure provide healthcare show improve patient survival public policy issue roche leader oncologya therapeutic area decade see little progress despite roche recognise trend complex intensive global effort cancer research interplay continue process focus area wide range restructure roche group focus entirely promise project pipelinevirology innovationdrivenhightech pharmaceutical key research area strong diagnostic businessesbecause exploit important contribution enormous combine knowledge base example advance treatment hepatitis businessesroche position play lead hivaidsroche leader transplan ing role advance new paradigms healthcare tation medicine anemia pipeline delivery tailormade product service deliver new product treat osteoporosis span entire healthcare spectrum asthma rheumatoid arthritis alzheimer disease emerge field predisposition screening diabete early detection prevention diagnosis therapy treatment monitor broad scientific year division invest billion swiss expertise area help patient andphysi franc research development figure cian early well health treat clearly signal commitment remain ment decision comprehensive product sciencedriven company remarkable depth portfolio clear strategic advantage quality pipeline widely recog steadily new era medical nised provide clear convincing evidence care increasingly tailor individual strong incompany capability patient productivity ofour partner relationship annual report roche group biomarker point way innovation research development well healthcare enoughto meet ambitious objectiveswe pursue technology leadership production areasbiotechnologyfor exampleis area steadily gain importance roche recent year roche sell medicine manufacture biotech nology combine revenue biopharma ceutical currently account group total prescription drug sale ability anticipate trend exploit potential new technology long roche strengthsour majority interest california base biotech pioneer genentech big successful company scientist roche pharmaceutical roche industry date way diagnostic work develop bio examplein additionwe ofeurope marker diagnose disease important biotech research manufacturing identify patient likely respond sitesin penzberg germany particular treatment help develop new drug diagnostic biomarker biological molecule provide diagnostic tool test expect play genetic information metabolic disease increasingly important role ensure process tremendous potential diag patient correctly diagnose early possible nostic search well medicine receive well available treatment help optimise use oflimite healthcare roche biomarker program key resource group strategy link pharmaceutical diag nostics expertise well target healthcare diagnostic industry vital contribu aim find biomarker reveal presence tion keep medical care affordableon disease clinical sign symptom appear averagelaboratory services account differentiate disease subtype relate total healthcare spendingyet informa condition help identify patient subgroup differ tion service provide tremendous poten response therapy provide lead tial make healthcare delivery potential drug target biomarker test improve efficient effective mean signifi ability diagnose disease open new pos cantly well costbenefit ratio sibilitie prevention help develop expenditure roche diagnostic work today medicine safe work well turn potential gain reality help costeffective relieve pressure health budget roche market test tell doctor anti roche company supply product viral treatment desire effect service segment invitro diagnostic patient tolerate certain medication market research institution hospital dosage group combine expertise discover commercial laboratory patient novel ing develop novel diagnostic test me analytical system feature powerful workflow icine put forefront emerge field automation capabilitiesare cut edge personalise medicine innovation laboratory technologyand con nectivity solution datum management system example stateoftheart product annual report roche group rocheby help health professional cope flood datum increasingly complex teststhey contribute sounder therapeutic deci sionmake increase role patient manage health farreache implication diagnostic industryas role continue growso demand handyeasytouse instru ments match precision accuracy laboratory treatment recommendation mean trend actionable health information scientific research provide deep insight cause diseasein addition enable fast accurate diagnosis insight reveal way identify risk factor detect presence ofdisease early possible todaythis expand opportunity start preventive treatment measure stage onset ofdisease avoid time understand ofthe reason medicine equally effective patient disease steadily increase future dnabase test help identify patient unlikely respond certain medicinescould adverse reaction simply benefit dose adjustmenta resultphysician able choose safermore effective option write prescription patient develop medicine test system meet today tomorrow need require extensive knowhow sizeable investmentsand roche prepare investment highly focused healthcare company roche equipped meet challenge ofa change marketplace excellent position advantage new opportunity growth combine knowhow diagnostic therapeu tic enable create sustainable value patientsphysician healthcare system annual report great certainty assess cervical cancer risk cervical cancer second leading cause death cancer woman trigger certain form human papillomavirus hpv see gynecologist regular screening test help detect hpv early test available date clear limitation pap test deliver inconclusive ambiguous result fail case detect precancerous condi tion compare pap test amplicor hpv test new molecular diagnostic assay develop roche launch europe provide signifi cantly accurate indication risk practical benefit healthy woman spare anxiety waiting result addi tional test importantly mean increase number patient start receive appropriate care early stage early diagnosis cervical cancer give patient chance recovery early detection early disease detect well chance treat effectively screen examina tion increase likelihood spot sign disease provide timely therapy benefit target screen particularly evident respect highrisk group early diagnosis help patient contribute control healthcare cost annual report available hpv test important triage abnormal pap smear screen warner khuh physician respected cancer researcher live birmingham alabamausa valuesthe potential importance ofthe new amplicor test human papillomavirus hpv predisposition early detection prevention diagnosis therapy monitor annual report pharmaceutical division brief pharma executive committee january william burns ceo division roche pharmaceutical george abercrombie north america jennifer allerton informatics eduard holdener development peter hug partner jonathan knowles research dominic moorhead finance control paul newtonsyms human resource charles sabbah strategic marketing claude schreiner western europe jan van koeveringe technical operation sale million chf operating profit exceptional item millions chf number employee key figure change change millions chf chf local currency sale sale roche prescription genentech prescription chugai prescription ebitda operate profit research development exceptional item annual report pharmaceutical roche pharmaceutical extend group market leadership oncology help outstanding clinical data product mabthera rituxan avastin tarceva launch avastin united states market resound success tarceva receive marketing approval united states late year drug class demonstrate survival benefit latestage lung cancer pan creatic cancer strong portfolio virology product back grow body solid datum bring benefit patient hepatitis hivaids influenza development successfully translate cuttingedge clinically differen tiate product good business prescription medicine exceed billion swiss franc revenue william mburnsceo division roche pharmaceutical annual report pharmaceutical result sale region roche pharmaceutical include genentech chugai continue deliver strong performance recording total sale million swiss franc represent increase latin america previous year local currencieswell ahead japan global market growth drive group oncologyvirology trans plantation franchise operating profit exceptional item increase advance europe local currency swiss franc north america million swis francsdespite sustained high level investment product launch activity division post significant increase profitability recording operate profit margin exceptional item compare operate therapeutic area margin increase product outlicensing activity exclude ebitda oncology total million swiss franc salescompare previous yearthe cancer ofthe main cause ofdeath sale roche nonprescription medicine busi industrialise country recent year see ness bayer ofchugais otc business lion major treatment advance particularly promis corporation complete end ing approach target cancer therapy specifically attack process drive cancerous cell leave healthy cell unharmed region roche group forefront ofthis innovation region contribute growth sale roche group oncology portfolio roche genentech north america earn revenue billion swiss franc ahead market fuel pri post gain oncology product marily strong demand avastin establish account group total prescription oncology brand hepatitis combination drug sale result strong perfor pegasys copegus oncology hepatitis mance expand market share franchise main contributor andconsolidate global lead important abovemarket growth europe therapeutic arearoche pharmaceutical market averagesale chugai japan rise group offer anticancer medicine compare local market growth ofin latin help extend life cancer patient america division record doubledigit sale unparalleled portfolio supportive care growth background steady market product improve quality oflife ofpeo recoverygrowth market ofthe asiapacific ple cancer region strong middle east africa hold despite political economic turbulence growth rate base local currency oncology portfolio mabtherarituxan herceptin avastin xeloda tarceva bondronat kytril furtulon neupogen neo recormon roferona neutrogin picibanil annual report pharmaceutical biotech production therapeu nonhodgkin lymphoma nhl group malignancies lymphatic system affect tic protein order approximately million people worldwide claim estimate life year mabtherarituxan world therapeutic monoclonal antibody indolent aggressive form nhl deliver strong growth particularly europe japansale ofthe prod uct benefit approval august europe firstline use indolent nhlnew datum survival benefit group ofpatientsin addition large clinical trial show maintenance treatment mabtherarituxan year highly effective patient indolent nhl biotechnology biopharmaceutical lead breast cancer common cancer therapeutic breakthrough number dis woman worldwide herceptin monoclonal anti ease notably cancer roche forefront body target treatment breast canceris advance biotechnology aim tailor subgroup ofpatient particularly world leader biopharmaceutical produc aggressive type tumour herpositive tion marketing account approximately breast cancersin herceptin generate sale ofalmost roche group include genentech chugai billion swiss francswith solid gain major own world biophar marketsadoption drug firstline therapy maceutical manufacturing capacity currently receive major boost junewhen combina build new facilities basel switzerland penzberg tion herceptin plus taxotere approve germany vacaville usa utsunomiya japan indication european union clinical cost billion swiss franc new plant study show herceptin combination help build roche leadership biotechnology taxotere taxol significantly prolong sur ensure sufficient manufacturing capacity vival ofpatient advanced breast cancerongo available meet expect demand group e clinical development aim establish new medicine thedrug combination hormonal treatment adjuvant therapy early breast cancer biotech manufacturing technique harnes natu ral biological process live cell use total sale ofxelodafor colorectal breast fulproduct product like innovative anticancer cer rise growth outside medicine avastin herceptin example united states impressive sale biopharmaceutical belong group ther growth united states impact apeutic protein know monoclonal antibodie half year number important produce help cell genet change marketplace prescription figure ically modify recombinant dna technique continue increase adoption ofthe prod cell culture grow special fermenter uctglobal sale expect accelerate call bioreactor grow multiply help new clinical datain august roche file secrete desire protein antibody culture application authority medium product harvest separate approval xeloda new indication adjuvant antibody biomass cell culture medium treatment colon cancer patient follow waste product concentrate purified surgery take orally xeloda far ready formulation final pharmaceutical convenient option patient product injectable regimen currently available annual report pharmaceutical avastin shut blood sale therapeutic area supply tumour transplantation dermatology metabolic disorder central nervous system infectious disease cardiovascular disease inflammatory disease bone disease virology tumour like body tissue need con anemia stant supply oxygen nutrient oncology create network blood vessel process call angiogenesis avastin medicine specifically inhibit tumour angiogenesis february genentech receive approval avastin united states use combination target protein call vascular endothelial chemotherapy patient previously growth factor vegf key mediator tumour untreated metastatic cancer ofthe colon rectum angiogenesis avastin interfere blood supply extremely successful launch demand essential growth cancer product market strong spread metastasis part body result sale ofalmost million swiss franc monthsin january avastin importance angiogenesis cancer receive marketing approval euin decem growth long recognise ber avastin approve switzerlandwhich scientist genentech establish vegfs criti open way registration medicine cal role promote formation new blood ves country worldwide guide sel tumour year later demonstrate swiss regulatory decision review pro specific antivegf antibody suppress cessesclinical trial repeatedly demonstrate tumour growth opening way development avastinwhen add chemotherapysignifi avastin world approve antiangiogenic cantly prolong survival patient metastatic cancer treatment colorectal cancer regardless chemotherapy datum release november show currently approve switzerland product significantly improve median israel combination chemotherapy patient survival patient relapse metastatic colon metastatic cancer colon rectum avastin cancersee research developmentp broad potential use number solid tumour groundbreake new biopharmaceuti tarcevaa breakthrough anticancer drug develop cal testimony success roche genentechosi pharmaceutical rochewa genentech longstanding alliance approve food drug administration fda november monotherapy advanced nonsmall cell lung cancer nsclc approval follow priority reviewwa base result phase iii trial show drug annual report pharmaceutical major product approval launch product generic indication country avastin bevacizumab firstline treatment combination chemotherapy usa metastatic colorectal cancer switzerland bonivabonviva ibandronate treatment prevention osteoporosis switzerland daily tablet herceptin trastuzumab metastatic breast cancer combination taxotere switzerland invirase saquinavir hiv disease formulation usa mabtherarituxan rituximab firstline treatment indolent nonhodgkin lymphoma switzerland neorecormon epoetin beta anemia indication prefille syringe switzerland pegasys peginterferon alfaa hepatitis prefilled syringe usa hepatitis switzerland hepatitis normal alt tarceva erlotinib second thirdline treatment advanced usa nonsmall cell lung cancer xenical orlistat prevention type diabete xendos data usa include supplemental indication update end january extend overall survival patient pretreate ifleft untreatedthe global market antianemia lung canceran application marketing authori product currently estimate worth sation evaluate authority billion swiss franc datum phase iii study show tarceva increase survival patient background continue price pressure metastatic pancreatic cancer add anemia market roche neo chemotherapy tarceva currently investi recormon chugais epogin post combine gate variety malignant disease sale billion swiss franc remain research developmentp lead product treatment ofrenal anemia respective marketssale neorecormon kytril control nausea vomiting cancerrelate anemia grow drive patient receive chemo radiation therapy successful launch penetration new undergone surgerycontinue perform onceweekly prefille syringe offer highly competitive marketplace patient high efficacy plus convenient dose sale ofbondronat grew strongly help transplantation continued rollout drug europe market follow approval prevention people worldwide receive lifesave skeletal event patient breast cancer organ transplant yearthank advance bone metastasis surgical procedure immunosuppressive ther apy prevent organ rejection transplant recipi anemia ent survive year new organswith longterm immunosuppressant treat anemia occur number ofre blood cell ment routinedoctor reduce use fall normal starve organ tissue relatively toxic immunosuppressant drug favour oxygen see patient medication minimal toxicity impair renal function chronic kidney dis cellcept ease ofpatient cancerthe potential longterm effect anemia include car roche global market leader transplan diovascular disease renal patient reduce tation medicine group transplan survival patient canceranemia fatal tation portfolio post sale billion swiss annual report pharmaceutical topselle product sale change product generic indication millions chf local currency mabtherarituxan rituximab nonhodgkin lymphoma neorecormon epogin epoetin beta anemia pegasys copegus peginterferon alfaa hepatitis ribavirin herceptin trastuzumab metastatic breast cancer cellcept mycophenolate mofetil transplantation rocephin ceftriaxone bacterial infection avastin bevacizumab metastatic colorectal cancer xenical orlistat weight loss weight control xeloda capecitabine colorectal breast cancer kytril granisetron nausea vomit induce chemotherapy radiation therapy follow surgery nutropin protropin somatropin somatrem growth hormone deficiency dilatrend carvedilol chronic heart failure hypertension coronary artery disease pulmozyme dornase alfadnase cystic fibrosis tamiflu oseltamivir treatment prevention influenza cymevene valcyte ganciclovir cytomegalovirus infection valganciclovir neutrogin lenograstim neutropenia associate chemotherapy roaccutaneaccutane isotretinoin severe acne activase tnkase alteplase tenecteplase myocardial infarction madopar levodopa benserazide parkinson disease jointly market roche genentech chugai market chugai jointly market roche chugai jointly market roche genentech franc increase roche flagship cytomegalovirus infection cmvvalcyte transplantation drug cellcept showing solid launch major market new growthdespite entry new competitorsthe indicationthe prevention ofcmv disease solid product share total immunosuppressant organ transplant patient remain market remain strong cellcept lead drug treatment cmv retinitis remains lead brand immunosuppressant hiv patient unite stateswith total prescription sale negatively impact sec virology ond half year change wholesaler buy ing pattern effect expect liver bodys important disappear half sale organ perform vital function zenapaxuse conjunction cellcept pre hepatitis viruse hbvhcv cause vent acute kidney transplant rejection increase acute chronic liver diseasepotentially lead million swiss franc liver failure cirrhosis cancer worldwide million people think chronically combine sale valcyte cymevene show infect hbv highly infectious pathogen solid growth valcyte responsible estimate million death global market leader prevention annuallymore million people annual report pharmaceutical breakthrough hiv medicine world infect hcvand million new case occur yearhepatitis main reason tackle drug resistance liver transplantation roche enhance leadership position hepatitis sale combination therapy pegasys plus copegus advance billion swiss francsat year end pegasys account ofboth global pegylate interferon market year new datum demonstrate significant benefit pegasys plus copegus hepatitis patient subgroup patient infect hiv patient persistently normal liver enzyme normal alt subgroup traditionally consider treat ment roche receive marketing authorisation develop jointly roche trimeris fuzeon europe normal alt indication novem major innovation hiv treatment ber regulatory filing approval combi novel mechanism action nation hivhcv coinfection submit make effective strain mid european union virus resistant drug united stateswe receive apositive opinion authority decemberand file drug resistance major challenge effective grant priority reviewroche com treatment hiv study report plete development programme pegasys patient antiretroviral treatment north america chronic hepatitis bwith extensive clinical trial datum infect strain virus resistant support use firstline treatment antihiv drug new medicine diseasemarkete application file combat drugresistant hiv urgently need europe united states january authority recommend fuzeon help address need approvalfollowing approval asiawhere hep new class drug inhibit hiv replication atitis particularly prevalentand december andit devastating effect immune system switzerlandpegasy pegy block virus enter human immune late interferon indication cell treatment subcutaneous fuzeon signifi world cantly reduce viral load increase number healthy immune cell enhance patient wellbee hiv worldwide pandemic world health quality life advance hiv treatment organization estimate million people prestigious international prix galien pharma include million childrenwere live ceutical innovation hivaid end year roche innovative drug diagnostic test roche launch comprehensive nursetopatient place forefront effort combat patienttopatient support initiative help hiv infection aid continue coach patient critical month work improve standard hiv care therapy time dramatic benefit worldwidefor information roche hivaids fuzeon see selfinjection rou initiative sustainability report visit tine wwwrochecom sale offuzeonfor treament ofhiv improve steadily reach million swiss franc year end roche trimeris work annual report pharmaceutical boniva make osteoporosis accelerate uptake fuzeon major physician patient education initiativesstrong treatment easier week treatment datum present yearconfirme virological immunological benefit good tolerability longterm treat ment fuzeonthese finding inclusion ofweek treatment datum product label support case expand use ofthe drugin fuzeon award prestigious international prix galien primary care global sale ofxenical slightly mar ket overall declinewhile sale fall significantly product experience steady pharmaceutical innovation find growth september european ing new drug mean make effec commission approve removal pre tive drug easy patient use treatment weightloss requirement disease involve common chronic product label base extensive longterm undertreated type innovation datum support drug efficacy safety widereache benefit base result landmark xendos study authority approve label osteoporosis cause gradual loss bone density change state xenical delay onset make bone brittle prone break affect reduce risk develop type million people worldwide especially woman diabetes obese patient menopause broken vertrebrae hip potential consequence toll follow patent expiry major euro inflict patient osteoporosis major impact pean market april generic erosion lead healthcare system people break hip decline sale ofdilatrenda lead beta block example usually spend day hospital agent hypertension chronic heart failure coronary artery disease cure osteoporosis treatment current bisphosphonate halt reverse relatively mild influenza season sale bone loss reduce risk fracture tamiflu decline despite initial order ofpandemic medicine complicated patient readiness supply preclinical test show daily weekly tablet morning tamiflu effective highly patho stomach remain upright eat genic human avian influenza viruscon half hour currently osteoporosis sidere likely source ofa pandemic strain patient stop therapy month expert call government establish derive little benefit stockpile tamiflu readiness possible pandemicroche work number ofgov bonivabonviva roche new bisphosphonate ernment determine requirementsit oncemonthly tablet osteoporosis increase tamiflu production capacity meet easy patient stay treatment additional demand plan increase minimise risk fracture patient unable tolerate oral bisphos phonate roche develop bonviva injection bonivabonviva develop people benefit innova oncemonthly oral treatment postmenopausal tive drug osteoporosisoneyear data twoyear multi annual report pipeline major development project successfully bring forward therapeutic area projectid projectproduct generic pharmacological class indication phase phase phase phase iii file hematology cera continuous erythropoietin receptor activator renal anemia nephrology cera continuous erythropoietin receptor activator cancerrelate anemia genitourinary disease gpcr modulator stress urinary incontinence gpcr agonist sexual dysfunction inflammatory autoimmune mabtherarituxan rituximab anticd monoclonal antibody autoimmune disease lupus nephritis bone disease mabtherarituxan rituximab anticd monoclonal antibody moderate severe rheumatoid arthritis mabtherarituxan rituximab anticd monoclonal antibody refractory rheumatoid arthritis tnf nonresponder integrin antagonist autoimmune disease rheumatoid arthritis multiple sclerosis kinase inhibitor rheumatoid arthritis integrin antagonist inflammatory bowel disease mra tocilizumab humanise antiil receptor mab systemic onset juvenile idiopathic arthritis mra tocilizumab humanise antiil receptor mab rheumatoid arthritis humanise anticd monoclonal antibody rheumatoid arthritis bonivabonviva ibandronate bisphosphonate treatment prevention osteoporosis cardiovascular enzyme inhibitor type diabete metabolic disease nuclear receptor modulator type diabete enzyme modulator type diabete nuclear receptor modulator type diabete enzyme inhibitor type diabetes nuclear receptor modulator dyslipidemia xenical orlistat lipase inhibitor obesity development japan xenical orlistat lipase inhibitor obesity label amendment insulin sensitiser insulin sensitiser type diabetes dyslipidemia cetp inhibitor dyslipidemia neurological gpcr modulator alzheimer disease psychiatric disease enzyme inhibitor alzheimer disease pde inhibitor alzheimer disease gpcr modulator depression enzyme inhibitor alzheimer disease pde inhibitor alzheimer disease gpcr modulator depression anxiety alzheimer disease schizophrenia anxiety oncology mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia linerelapse mabtherarituxan rituximab anticd monoclonal antibody maintenance indolent nhl omnitarg pertuzumab antiher monoclonal antibody solid tumour breast cancer lung cancer ovarian cancer prostate cancer tarceva erlotinib egfr inhibitor nsclc ndrd line tarceva erlotinib egfr inhibitor nsclc line combination chemotherapy tarceva erlotinib egfr inhibitor adjuvant nsclc tarceva erlotinib egfr inhibitor pancreatic cancer tarceva erlotinib egfr inhibitor glioblastoma multiforme tarceva erlotinib egfr inhibitor nsclc line combination avastin enzyme inhibitor solid tumour enzyme inhibitor epothilone solid tumour enzyme inhibitor solid tumour monoclonal antibody metastatic breast cancer enzyme inhibitor solid tumour humanise anticd monoclonal antibody hematologic malignancy enzyme inhibitor epothilone solid tumour xeloda capecitabine fluoropyrimidine metastatic colon cancer line combination treatment xeloda capecitabine fluoropyrimidine adjuvant colon cancer combination treatment xeloda capecitabine fluoropyrimidine adjuvant colon cancer monotherapy xeloda capecitabine fluoropyrimidine adjuvant breast cancer avastin bevacizumab antivegf monoclonal antibody metastatic colorectal cancer line avastin bevacizumab antivegf monoclonal antibody adjuvant colon cancer avastin bevacizumab antivegf monoclonal antibody pancreatic cancer tivegf tib avastin bevacizumab antivegf monoclonal antibody renal cell carcinoma avastin bevacizumab antivegf monoclonal antibody nsclc avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer avastin bevacizumab antivegf monoclonal antibody ovarian cancer linerefractory enzyme inhibitor solid tumour herceptin trastuzumab antiher monoclonal antibody adjuvant breast cancer herceptin trastuzumab antiher monoclonal antibody metastatic breast cancer combination hormone therapy herceptin trastuzumab antiher monoclonal antibody advance gastric cancer bondronat ibandronate bisphosphonate metastatic bone pain tumour type solid tumour oncology oncology respiratory disease daclizumab anticd monoclonal antibody asthma dual integrin antagonist asthma nuclear receptor agonist emphysema viral antibiotic bacterial infection infectious disease polymerase inhibitor hepatitis pegasys peginterferon alfaa chronic hepatitis invirase saquinavir protease inhibitor hiv tablet participation lucentis lucentis ranibizumab fab fragment antivegf agerelate macular degeneration genentech amd fab xolair xolair omalizumab antiige antibody pediatric asthma peanut allergy participation antioxidant coronary heart disease chugai chs recombinant parathyroid hormone osteoporosis vitamin derivative osteoporosis cal antipthrp mab bone metastasis chc polyglutamatetxl solid tumour ovarian cancer nsclc femara femara letrozole aromatase inhibitor breast cancer antevas antevas radical scavenger subarachnoid hemorrhage motilin agonist gastroparesis irritable bowel syndrome val liver regenerator post hepatectomy optin opportunity brfc fusion protein rheumatoid arthritis genentech mabtherarituxan rituximab anticd monoclonal antibody multiple sclerosisanca associate vasculitis sle topical hedgehog antagonist basal cell carcinoma pro apoltrail cancer vegf vegf recombinant vegf diabetic foot ulcer pro optin opportunity bal antifungal fungal infection glp type diabetes vascular target agent solid tumour modulator solid tumour calcineurin inhibitor acute renal transplant rejection nonnucleoside reverse transcriptase inhibitor hiv external partner project currently nme pharmaceutical division pipeline genentechbiogen idec kosan bioscience kos earlystage development phase enter phase clinical testing phase chugai protein design labs phase iii file genentech pro sankyo project enter phase move phase phase phase iii glaxosmithkline novartis ophthalmic nippon shinyaku novartis tanox phase transition preclinical clinical development japan tobacco jtt biogen idec phase initial study healthy volunteer possibly patient memory pharmaceutical mem curis phase efficacy tolerability dosefinde study patient memory pharmaceutical mem amgen immunex phase iii largescale study patient statistical confirmation ofsafety efficacy genentech basilea pharmaceutica bluetype signify indication blacktype additional indication genentechosi pharmaceutical ipsen bim current december kosan bioscience kos antisoma dmxaa ipsen arqule arq therapeutic protein antisoma isotechnika small molecule ipsen medivirfoldout pipeline pharmaceutical national study oncemonthly oral boniva research project major therapeutic area effectivewelltolerate convenient alter dec native current daily weekly oral bisphospho nate regimen potential improve longterm treatment adherence addition new oncology datum multinational study injectable neurological psychiatric disease boniva show injectable bis phosphonate effective administer viral disease monthsoffere osteo respiratory disease porosis patient great choice especially help genitourinary disease e unable tolerate oral therapythe inflammatory autoimmune bone disease monthly oral formulation file cardiovascular united statesthe european union switzer metabolic disease land prepare launch partner glaxosmithkline marketing application boniva twomonthly monthly intravenous injection submit fda end aim develop wellprofiled medicine add major product significant value patientsphysician payer ofour therapeutic area ofinterestpharma rocephin remain world lead injectable research apply strategy steadily antibiotic post total sale bil increase quantity quality lion swiss francsrocephin strong year compound move development screen united states sale grow european undesirable characteristic sale ofthe product decline expect discovery stagepreclinical clinical riskdefin delay introduction ofgeneric italy ing study traditionally conduct later phase move phase sale roaccutaneaccutanefor severe acnefell result long phase cycle times onethird decline believe increase quality ofthe compound largely market entry ofcompeting gener enter latermore costly development phase ics united states europe additionwe align drug safety evaluation roche work closely health authori discovery right marketing tie introduction enhance har seamless process monise pregnancy prevention programme woman take roaccutaneaccutane isotretinoin pharmaceutical division pipeline cur member statesin united states roche rently include new molecular entity nme work fda generic manufac phase phase turer create register ofall patient treat phaseii phase iii file product contain isotretinoin register expect launch july roche research development file replace current accutane programme investigational new drug application fdaa significant increase previous year research development foldout pipeline detail regularly roche pharmaceutical invest billion swiss update information roche pipeline franc ofsalesthis visit httpwwwrochecomhomeinvestor put industry average show invpipelinehtm strong commitment innovation annual report pharmaceutical roche expect advance project major development activity phase clinical testing main growth area oncology roche increase oncology number project roche genentech pursue comprehen end currently research pro sive clinical programme investigate use ject seven therapeutic area develop avastin number ofchemotherapeutic agent ment project therapeutic area advance colorectal cancer adjuvant ther rochemanage projectseleven termi apy follow surgery avastin mechanism nate phase phase action relevant number malignant phase iionly product pemtumomab tumourswe investigate drug poten terminate phase iii tial clinical benefit cancersinclude non small cell lung cancerpancreatic cancerrenal cell innovation network carcinoma breast cancerapproximately patient expect enrol clinical trial roche pharmaceutical continue worldwide year expand access innovative researchtechnolo gy compound hubandspoke tarceva design interfere molecular strategy combine strong inhouse signal stimulate tumour cell growth external partnership alliance numerous type cancer currently investigate variety malignant disease november roche strengthen global global alliance rochegenentechosi pharma research network open new pharmaceutical ceutical chugai tarceva evalu centre shanghai china new facility ate combination avastin focus medicinal chemistry research lead generation optimisationcomplemente major programme explore role ofherceptin activity group centre adjuvant breast cancer ofxeloda adju vant set colon breast cancer continu roche genentech important progress ingas exploratory trial potential coordination research activity agree benefit earlystage molecule dis ment sign set framework tinct mechanism ofaction number ofcancer joint projectsfollowing review discovery portfolio oncology immunology roche scientist identify class small researcher evaluate potential molecule activate key tumour suppressor joint project pathway protect cell malig nant new research offer completely roche sign new research new strategy cancer therapy technology agreement product agree ment include important one oncology hematology nephrology anemia arqule syrrx virology pharmasset structural development cera continuous ery genomix vascular disease japan tobacco thropoietin receptor activatorfor treatment year alliance exist renal cancerrelate anemia progress ner include affymetrix anadys bioxell elan trackcera represent major advance anemia evotec memory norak expand management recruitment global phase iii amend enhance valuein additionroche renal anemia study advance phase sell right tasmar valeant pharmaceutical iii study cancerrelate anemia start right soriatane united states midroche plan file marketing applica connetic tions united states annual report pharmaceutical rheumatoid arthritis asthma rheumatoid arthritis autoimmune dis novel nonsteroidal oral treatment order characterise joint inflammation target inflammatory process underlie treat result progressive joint asthma result phase study show destruction ultimately loss function good safety tolerability profile cause unknown shorten life base initial efficacy dataroche continue expectancy affect major organ systemsless development ofthe moleculewith phase iib stud patient able work ies schedule begin form everyday task year develop disordernearly million people suffer roche protein design labs agree worldwide codevelop daclizumab use asthma relate respiratory condition base positive phase roche genentech biogen idec develop study datum patient moderate severe mabtherarituxan treatment ofrait asthma daclizumab currently approve bcell deplete agent study dis immunosuppressant transplant patient ease development progress track brand zenapax global filing initial indication patient inadequate response currently prescribe vascular disease biologic plan second halfof roche license innovative cetp positive datum phase study dancer inhibitorcurrently phase developmentfrom announce novemberin study patient japan tobacco addition potent moderate severe receive infusion highly selective ppara agonist license mabthera twoweek period combina nippon shinyaku phase development tion stable dose ofmethotrexate experienced molecule show raise level ofgood improve symptom compare patient cholesterolor hdlcwhich help prevent receive placebo methotrexate coronary event target approach see new frontier cholesterol control development ofmra antiinterleukin recep tor antibody progress track november roche decode genetic phase iii study ofthis novel biopharmaceutical announce formation ofa threeyear collabora commence europe united states tion develop commercialise phosphodi end esterase pde inhibitor prevention treatment vascular disease include stroke diabete new alliance expand scope collabora work continue development insulin tion company genetically sensitiser treatment oftype diabetes drive target discovery activity phase follow new guidance fda data ofdrug research requirement class drug belongsroche decide wait result ongoing longterm toxicity study start phase iii clinical trialsthe toxicity study complete halfof treatment oftype diabete clinical development decision entry phase expect visit wwwrochecomhomedivisionshtm novel compound represent genera formore information roche pharmaceutical tion oforal antidiabetic medicine annual report doctor tell hcv difficult treat thank pegasys virusfree monique wald live daughter near frankfurt maingermanyshe probably infected withhcv genotype early sbut diagnose chronic hepatitis predisposition early detection prevention diagnosis therapy monitor annual report pegasys highly effective medicine forallhepatitis virus genotype hepatitis major cause acute liver inflamma tion cancer leave untreated cause chronic progressive liver damage lead cirrhosis buildup scar tissue liver ultimately liver failure death hepatitis virus hcv properly identify cause hepatitis unknown condition refer nona nonb hepatitis year virus hasmutate genetically distinct strain identify genotype differ response treatment pegasys provide significant benefit patient hepatitis matter viral genotype infect molecular structure pegylation allow therapeutic drug level sustain week dose pegasys dis tribute readily liver primary site infec tion pegylate interferon available readytoadminister solution clinical trial show excellent treatment come patient receive pegasy combine copegus half patient infect genotype form hcv difficult treat achieve sustained virological response mean virus long detect intheir blood prevention prevention involve identify possible eliminate risk factor particular disease reduce minimum preventive treatment medicine intervention delay onset overt illness stop disease progress limit organ tissue damage complication annual report diagnostic division brief diagnostic executive team january heino von prondzynski ceo division roche diagnostic silvia ayyoubi human resource heiner dreismann molecular diagnostic staffan diabetes care christian hebich finance service tiffany olson market development volker pfahlert apply science burkhard piper centralized diagnostic jrgen schwiezer emea region europe middle east africa robert yates business development sale millions chf operating profit exceptional item millions chf number employee key figure change millions chf change chf local currency sale sale diabete care near patient testing centralized diagnostic molecular diagnostic apply science ebitda operate profit research development exceptional item annual report diagnostic successful year reason sixth straight year grow significantly fast market increase market share time improve operate profit margin novel technology open door new era diagnostic today cuttingedge research genetic genomic proteomic tomorrow diagnostic test accurate rapid efficient dna chip example help identify disease predisposition early stage pave way preventive action medium term contribute significant saving healthcare cost heino von prondzynskiceo division roche diagnostic annual report diagnostic result sale region roche diagnostic remain growth track sale advance local currency swiss francssale grow significantly fast market ofthe division business area europemiddle eastafrica lead particularly strong gain diabete care japan molecular diagnostic immunochemistry seg asiapacific mentsas resultthe division reinforce posi tion global market leader north america iberialatin america profitability improve furtherthe division oper ate profit margin exceptional item reach ebitda margin climb percentage point figure set new industry benchmarkoperating profit exceptional item increase million business area swiss francswhile division ebitda rise million swiss franc diabetes care roche diabetes care remain lead pro region viderofsolution well diabete management sale grow local currency roche diagnostic outpace market accuchek advantage accuchek regionsonce sale advance doubledigit compact blood glucose meter rate iberialatin america topselle product asiapacific region especially strong gain report chinaindiakorea tai global diabetes market characterise wanthe division continue expand market rise cost pressure new treatment option leadership region sale increase customer demand sophisti japanhelpe success ofthe division cat powerful diabetes management system diabete careblood screen immunochem meet challengesroche diabetes care istry business adjust sale expand accuchek product family product line north american stateoftheart accuchek dtronplus insulin sale rise comparable basis increase pump pump carry accuchek market growth rate diabete launch new accu management product molecular diagnostic chek pocket compass diabete management immunochemistry big growth seg software package personal digital assistant ment europesale market region complete circle care allow user include middle east africa advance record track datum blood glucose yearand grow significantly fast meter insulin pumpthis isthe roche market product link blood glucose measurementanaly sis ofpatient datum insulin delivery see launch accuchek multiclix world lance device use integrate lancet drummulticlix offer enhance hygiene safety lancet automatically retract sixlancet drum immediately use annual report diagnostic topselle product line sale change product line market segment business area millions chf local currency accuchek diabete management diabetes care cobas integra clinical chemistry centralize diagnostic roche hitachi elecsys immunochemistry centralize diagnostic amplicor test clinical molecular molecular diagnostic cobas amplicor diagnostic cobas ampliscreen nucleic acidbase molecular diagnostic blood screen coaguchek coagulation monitoring near patient testing exclude hia homogeneous immunoassay division manufacture blood glucose sale coagulation monitor product seg meter china production site ment roche far large market ineurope north americathe new production share grow demand facilitywhich operational mid fuel mainly continue trend system strengthen roche diagnosticspresence atic anticoagulation managementmore highgrowth chinese market give division european health insurer begin reimburse broad base compete successfully cost patient selfmonitore far east wholein china alonethere benefit document interna currently million people live tional clinical trial selfmonitore diabetesand figure project increase shownfor exampleto significantly reduce risk fold tothree decade thrombosis patient artificial heart valve mid fda issue letter cite certain deficiency manufacturing process docu roche diagnostic leader hospital mentation disetronicthe insulin pump manu pointofcare segment rapid testing product facturer acquire roche early year use hospital accident scenesthe deci procedure process question sion tighten focus core area modify conform roche positive impacta reflect good sale ofcardiac group worldwide quality standard roche assay large increase new placement work closely fda official preparation blood gas electrolyte analysersplacement pende fda reaudit ofthe burgdorfpro omni multifunctional blood gas analyser duction site switzerland follow successful exampleshowe fourfold increase completion reaudit roche quickly start sale newgeneration insulin global rollout urisys successfully pump united states complete compact system stan dardise urinalysis design use doctor near patient testing office small laboratory roche near patient testing lead supplier centralize diagnostic product service rapid diagnosis pointofcare settingsfrom ambulance inten roche centralized diagnostic lead supplier sive care unit doctor office patient integrate total solution clinical laborato homessale business area grow local riesreporte abovemarket sale growth currency local currency annual report diagnostic mount pressure contain medical cost license marker hscrp high sensitivity healthcare delivery efficientcombine creactive protein assess cardiovascular shortage ofskille laboratory staffis fuel riskhscrp important cardiac marker demand costeffective fully automate inte division portfolio includes grate laboratory system biomarker test heart attack heart failure modular analytic swa serum work area segment roche leader molecular diagnostic meet need oftoday laboratory marketcom bin clinical chemistry immunochemistry roche molecular diagnostic remain undis test single platform system put market leader highgrowth segment centralize diagnosticskey growth driver sale diagnostic product local currencieswhile sale ofenzyme industrial cus performance business area largely drive tomerswhich account small percentage strong rise immunochemistry saleswith revenuesshowe gain ofblood screening acquisition igen provide important addi women health product main growth tional stimulus growthcomplete february driver strategic transaction secure roche right electrochemiluminescence ecl sale blood screening segment advanced technology underlie elecsys line ofimmuno impressive viral test chemistry productsfrom prod screen unit blood worldwide uct line consistently achieve sale growth nucleic acidbased testing system new placement elecsys system look viruse directlyrather anti reach record highand sale rise body form response infection test medium term roche diagnostic aim base nucleic acid technology nat help leader immunochemistrya growth ensure availability safe blood blood market currently value billion swiss franc product soon new tenyear agreement longstanding saw sign major agreement japanese partner hitachi hightechnologie areaone ofthe agreement extend exclu bring step close achieve sive contract japanese red cross goal roche hitachi continue develop additional year provide automate laboratory solution set new stan korean red cross use roche test screen dard innovationjust blood donationsthe agreement past year german red cross mark roche entry german blood screening market division continue invest technolo realtime pcr instrumentsthese instrument gy automate step precede base secondgeneration pcr polymerase follow actual testing laboratoryfor example chain reaction technology pcr technology roche diagnostic extend cooperation copy dna fragment sample million oftime agreement preanalytical system pvt enable detection minute probenverteiltechnik germanya rein amount ofbacteria virus force division lead supplier oftotal labo ratory solution addition application clearance cobasampliscreen hbv test screen donor cardiovascular testing segmentcentralize bloodfor hepatitis virus submit diagnostic increase availability fda probnp key marker heart failure outlicense agreement year filing submit fda expand product portfolio expand indication cobas ampliscreen annual report diagnostic gender matter hiv hcv product nat testing cadav eric fluid hiv hepatitis virusclearance product indication help increase safety oforgan tissue donation division add important test womens health portfolio successful european rollout amplicor hpv test capable identify clinically relevant human papillomavirus hpv genotype hpv infection recognise lead cause cervical cancerfrance european country approve reimbursement testwe expect hpv test significant positive impact diagnosis treatment cervical cancer awareness significant health dif research developmentp ference man woman new recently researcher test chlamydial infection gonorrhea begin systematically investigate differ common sexually trans ence finding startling mitte diseasesposted doubledigit sale growth example recent study show risk roche molecular diagnostic maintain arteriosclerosis increase dramatically woman lead position fiercely competitive virol follow hormone change occur ogy market business area quantitative test menopause contrary widespread belief hepatitis qualitative test hepatitis heart disease claim live woman major growth driversin addition man susceptible genderspe hepatitis genotyping test available cific disease like breast cancer lead forresearch use united states cause death woman aged woman frequently victim sexually transmit sale genomic segment show double disease man infertility common complica digit growth strong gain tion chlamydia infection cervical cancer amplichip cyp test world micro usually precede infection human arraybase test clinical diagnostic use papillomavirus hpv launch year europesince jan uary clear market good reason devote united statesthis novel test provide valuable research women health area information assess bodys ability mean new roche diagnostic metabolise medication vary greatly world broad portfolio women health test individualsit new generation include test osteoporosis fertility diagnostic test identify clinically relevant infectious disease new hpv test illustrate genetic differencesthus help physician select roche rely heavily modern molecular tech appropriate drug dosage nologie hope set new standard patient early detection treatment breast cancer ovarian cancer disease apply science roche apply science supplier ofreagent hightech systems scientific industrial research major focus area genomic proteomic follow weak business annual report diagnostic dna chip tiny hightech achieve excellent growth sale rise wonder big future local currency growth lead sale lightcycler reagent apply sciences industrial business major contribution come new placement oflightcycler instru ments placements dna amplification system continue increase steadily particularly inhighgrowth market asiapacific region research development roche diagnostic invest million swiss franc research developmentsignifi cantly competitor division dna chip establish tool lay foundation future success concen research tiny device conquer trate research effort primarily new world help doctor deliver fastestgrowe segment molecular diagnostic personalise healthcare base insight diabetes immunochemistry small important genomic difference diabetes care dna chip know gene chip micro arrays thumbnailsize chip embed main focus develop accuchek sys thousand precisely arrange dna fragment tem offer optimum userfriendliness like molecular magnet attract design living diabetes easierfor specific dna sequence sample target start mean provide patient system sequence present sample react hybridise analyse data glucose monitor complementary fragment chip pro insulin pump turn datum actionable ducing fluorescent dot visualise information patient doctorsand special laser equipment result pattern mean develop stateoftheart insulin help identify genomic difference affect indi pump like accuchek spirit schedule vidual response treatment result launch enable patient amplichip cyp test example doctor match insulin dose closely well assess quickly patient metabolise individual need certain drug select drug dose additionproject way develop inte dna chip able analyse huge number grate system combine glucose measure gene simultaneously reason ment datum management insulin delivery play indispensable role research division work miniaturise device bright future area clinical diagnostic component minimally invasive technology test distinguish different continuous blood glucose monitoring system cer viral infection genetic signature treatment tailor precisely aim design pump come close patient disease possible mimicking natural pattern ofinsulin release healthy individual ultimately develop artificial pancrea deoxyribonucleic acid dna material carry genetic information annual report diagnostic major product launch business area product diabete care accuchek dtronplus insulin pump accuchek brand accuchek blood glucose monitoring system capillary fill safety feature accuchek multiclix multiple lancing system integrate lancet drum accuchek pocket compass diabete management software accuchek safe tpro plus disposable lancing device adjustable depth set accuchek spirit flexible menudriven insulin pump near patient testing datacare pointofcare datum management software update omni bloodgaselectrolyte combianalyser family expansion centralize diagnostic elecsys afp update reagent assessment germ cell tumours elecsys cpeptide assay measure cpeptide human serum plasma urine elecsys ferritin update reagent assessment iron metabolism elecsy hiv combi combine hiv antigen antibody assay elecsys pnp bone formation marker treatment monitor osteoporosis elecsys pth update reagent assessment parathyroid function elecsys treatment monitoring skin cancer sta cephascreen coagulation test urisys urinalysis system molecular diagnostic amplichip cyp test microarray drug metabolism ivd amplicor hpv test test kit microwell plate format qualitative determination human papillomavirus ivd lineararray hcv test test hepatitis virus genotype research use ivd clinical use european mark certification conformit europenne near patient testing instrument connectivitythe cobas mod ular serum work area platform new trend decentralise testing diagnostic generation analyser currently devel testing outside laboratory continue ope specifically mediumthroughput labora mediumterm goal roche near patient testing tory supply portable device capable ofperforme important coagulation test business centralize diagnostic invest area add new product portfolio development ofnew immunoassaysresearch work cardiac marker test include ntprobnp protein produce encourage assay cardiac reader systemthis assay preliminary datum new breast cancer markersand valuable tool rule heart failure marker disease include colorectal point ofcare cancer rheumatoid arthritis cardiovascular conditionsare investigate centralized diagnostic molecular diagnostic roche centralized diagnostic working develop costeffective total laboratory quarter roche expect receive solution focus workflow automation european mark certification lineararray annual report diagnostic key product launch schedule business area product diabetes care accuchek aviva highend successor advantagesensor blood glucose monitoring system accuchek compact plus blood glucose monitoring system onestep handle integrate strip lance device accuchek pocket compass diabete management software accuchek spirit flexible menudriven insulin pump usa near patient testing cardiac probnp test strip use cardiac reader diagnosis monitor ofchronic heart failure cobas hospital pointofcare datum management software centralize diagnostic cholinesterase assay assessment liver function available liquid reagent mpa mycophenolic acid new product monitor roche immunosuppressive drug elecsys prolactin optimisation macroprolactin detection elecsys vitamin new product extension bone marker portfolio ecl platform dedicated hbac glycate hemoglobin analyser basis cobas integra molecular diagnostic amplichip cyp test microarray drug metabolism ivd amplichip leukemia test detection different subtype research use cobas ampliprep cobas taqman integrate system sample preparation anddnarna analysis hiv hcv hbv cobas ampliscreen hbv test detection hcv hiv rna hbv dna inhuman plasma ivd cobas taqman test detection chlamydiace ivd lightcycler factor test detection mutation clotting factor leiden ivd lineararray hcv test hepatitis virus genotype ivd lineararray hpv test human papillomavirus ivd sepsis test detection bacterial fungal dna blood ivd apply science htc system highend realtime pcr system throughput wells lightcycler cesw ivd version lightcycler dna amplification system quant pcr master taqman generic pcr master mix use common real time pcr instrument ivd clinical use european mark certification conformit europenne hpv test identify hpv genotype meet evergrowe demand blood test available research use blood product laboratory frequently screen united states pool sample multiple donor save time money increase risk roche molecular diagnostic currently plan thata virus undetectedtwo roche instru ning launch rapid sensitive chlamydia ment design address safety issue cur assay cobas taqman instrument real rently development schedule launch time pcrthis assaywhich available outside united states blood screening amplicor instrumentwill major addition system blood screening system taqman menu chlamydia assay dedicate fully automate instrument nucleic acidbased test frequently possible screen individual sample perform molecular diagnostic laboratory quickly reliably costeffectively system annual report diagnostic meet great enthusiasm interna tional blood service conference moreoverroche molecular diagnostic develop ing clinical diagnostic test use amplichip pcr technology base late advance genomicshere roche working affymetrix usa decode genetics iceland discover additional genetic variation mark er useful development ofnovel test particularly complex disease like leu kemia collaboration agreement epigeno mic germany yield resultsin epigenomic identify number marker day facilitate early detection ofbreast colorectal cancer step develop test biomarker apply science business area develop innovative reagent system research life sciencesparticularly genomic proteomic product portfolio genomics expand launch htc high throughput cycler system realtime pcr analyser feature high sample throughput capabilitie broad menu test innovative test identify genetic variant schedule launch visit wwwrochecomhomedivisionshtm information roche diagnostic annual report tailormade solution different kind laboratory time essence truer clinical laboratory huge number blood serum urine sample process day large laboratory perform test hour understandably laboratory turn automate integrated solution save precious timethat laboratory want maximum cost efficiency insist absolute system reliabil ity go say modular highthroughput analyser modular ana lytic swa serum work area deliver count combine clinical chemistry immunoassay capability single platform system allow user consolidate score test blood chemistry like cholesterol electrolyte protein hormones biomarker cancer osteoporosis cardiovascular infectious disease result sample process single pass sample load automatically transfer test position system improve workflow efficiency help reduce labour cost system modular say configure meet laboratory individual need diagnosis cope todays broad range test high sample workload laboratory require system combine high sensitivity precision speed userfriendliness critical providing physi cians fast accurate diagnostic information need treat patient early target diag nostic testing test monitor dis ease progression treatment response key achieve successful treatment outcome annual report fast accurate test result critical effective care laboratory physician imme mautewho live berlingermanyprovide communitybased practitioner vital information decision patient carein businessefficientreliable system predisposition early detection prevention diagnosis therapy monitor annual report board director executive committee board directors executive committee annual general meeting april richard laube head roche consumer bruno gehrig lodewijk vink healthwhich sell bayersteppe elect new member ofthe board ofdirector executive committee end date board appoint gehrig sale close december suc vicechairman independent lead director cessfully lead group otc business name chair board remunera appoint executive committee tioncommitteemr vink appoint board ofdirector like finance investment committee opportunity thank laube significant contribution company wish current board term ofjohn bellandr hoff success future endeavours mann franz humer end annual general meetingon february end board director vote gentleman agree stand reelec tointroduce number ofstructural personnel tion boardif reelectedchairman change expand strengthen executive ofthe board franz bhumer continue committee change effective director serve executive capacity january include appointment rocheand majority seat board william mburnswho head group pharma hold independent director ceutical division ceo division roche phar maceutical appointment heino von prondzynskihead diagnostic divisiona ceo division roche diagnostic chief financial officer erich hunziker appoint deputy head ofthe executive committee addition follow key senior manager havebeen appoint permanent participant executive committeeeduard holdenerhead global pharma development peter hughead pharma partnering staffan head roche diabete careand rolfschlpferhead ofcorpo rate communications osamu nagayama presi dent ceo ofchugaiwho participat ing meetings executive committee requiredhas name permanent participant complete medical studieseduard hold ener swiss work internist annual report board director executive committee board ofdirector january leave john bellrolfhnggipeter brabeckletmathe bruno gehrigandr hoffmannfranz bhumerlodewijk jrde vinkdeanne juliuswalter frey andreas oerihorst teltschik year birth term end election board director franz humer chairman prof bruno gehrig vicechairman independent lead director rolf hnggi vicechairman prof john bell peter brabeckletmathe lodewijk vink walter frey andr hoffmann deanne julius andreas oeri prof horst teltschik secretary board directors gottlieb keller finance investment committee january audit corporate governance committee remuneration committee presidiumnomination committee nonexecutive member executive member committee chairman annual report board director executive committee oncologist hospital switzerland earn degree economicsrolfschlpfer clinical research university kansas swissheld management position theunite stateshe join group marketing communicationshe partner member oncology group roche clinical manage director consultancy firm research organisation appoint head wirz identity join roche head group holdener charge corporate communication include pharma development roche japan internal external communication public appointment head global pharma affair development recent year group steadily pursue peter hug swiss phd eco strategy reshape innovative nomic join roche work healthcare company focus pharmaceutical variety position pharma marketing diagnostic businessesand change switzerland canada greece later gen executive committee mark step eral manager group affiliate uruguay direction new structure give broad switzerland spain career roche leadership base clearly define deputising include year head roche diagnostic arrangement enhance transparency func business germany september hug tions vital strategy ofinnovation assume current position head pharma directly represent executive commit partneringwhere responsible group tee important business area strategically vital network collaboration corporate departmentsthis help ensure alliance group continue ability revitalise strengthen management team staffan ekwho swedish degree busi new structure allow chairman ceo franz ness administrationbegan career market bhumer focus strongly role e consultant join pharmacia phar chairman ofthe board ofdirector maceutical group work year appoint head diabete care unit boehringer mannheim german diagnostic company acquire roche ashead roche diabetes carehe manage business area account large share ofroche diagnosticssale annual report board director executive committee executive committee january leave jonathan kcknowlesheino von prondzynski william mburnsfranz bhumererich hunzikergottlieb akeller year birth position executive committee franz humer chief executive officer erich hunziker chief financial officer william burns ceo divisionroche pharmaceuticals heino von prondzynski ceo division roche diagnostic prof jonathan knowles research gottlieb keller corporate service human resource permanent participant eduard holdener global pharma development peter hug pharma partnering staffan diabetes care rolf schlpfer corporate communication osamu nagayama president ceo chugai secretary pierre jaccoud executive committee statutory auditor kpmg klynveld peat marwick goerdeler roche holding ltd principal auditor john morris group auditor compliance officer andreas greuter direct phone number deputy head executive committee january annual report beat cancer treatment receive mabthera adam morris data manager professional soccer player live newtownwales diagnose nonhodgkin lymphoma ofthe bonea aggressive type ofcancerin predisposition early detection prevention diagnosis therapy monitor annual report mabtherarituxan smart drug lymphoma nonhodgkin lymphoma nhl common cancer lymphatic system result defective production white blood cell mabthera market rituxan united states canada japan therapeutic antibody bind particular protein surface normal malignant cell type white blood cell recruit bodys natural defence attack kill marked cell immune system work healthy new cell produce thebone marrow treatment return mal level month combination mabthera chemotherapy new treat ment year improve survival patient aggressive nhl date patient world treat mabthera therapy clinically differentiate medicine com bin intervention essential com ponent effective treatment disease diagnostic test help physician choose appropriate drug dosage monitor tients response medication play increasingly important role therapy physician tailor treatment patient individual need improve clinical outcome costefficiency annual report corporate governance corporate governance roche take account organisational structure board principle govern management director supervision company system check balance ensure accountabilityin addition roche board director organise comply exist legal internal ensure group business conduct company regulation roche operate responsibly focus longterm value accordance requirement set creation year ago board company article incorporation bylaw director roche holding ltd delegate certain roche meet requirement swx swiss responsibility committeesthese com exchange swx corporate governance directive mittee include commentary subscribe presidium ofthe board ofdirector swiss code good practice corporate nomination committee governance promulgate business federa chairmanfranz bhumer tion economiesuisse aim serve diverse audit corporate governance committee interest stakeholder particular chairmandeanne julius employee shareholder holder roche non finance investment committee voting equity security customer bal chairmanrolfhnggi ance fashionthis commitment isreflecte remuneration committee operating business focus innovation chairmanbruno gehrig value creation management culture characterise modernappropriate standard committee presidium chair ofcorporate governance independent director combine print annual report key bylaw board director contain link roche website wwwrochecom details internal structure board enable reader gain snapshot allocation authority responsibility report date uptodate overview mandate board committee infor company key corporate governance information mation control mechanism available annual report contain information board dealing corporate management available december give yearwhile publish internet internet provide source permanent constantly update information company article bylaw article incorporationthe bylaw cur board director independent lead ricula vitae member board direc director request member tor executive committee regularly convene board meeting attendance update available internet chairman roche board meet require information year assess chairman performance meeting hold absence httpwwwrochecomhomecompany chairman chair independent lead comgovcomgovbylawshtm director annual report corporate governance remuneration remuneration pay pro rata board membership period january march remuneration member board ofdirector members board director otherwiseno additional remuneration pay receive remuneration show table member ofthe board ofdirector serve board remuneration member board director special additional compensation remuneration remuneration committee member chf chf chf humer gehrig hnggi bell brabeckletmathe ljr vink frey hoffmann julius oeri teltschik total committee membershipyear exclude member presidium vicechairman chf remuneration pay chairman board humer executive member board director deduct agree salary remuneration member executive committee remuneration serve independent lead director vicechairman pro rata period april december remuneration serve vicechairman board pro rata period april december special remuneration additional time require julius evaluate new auditor remuneration special remuneration addi remuneration member executive tional compensation pay nonexecutive mem committee ber board director serve member executive committee aforementione capacity total swiss receive salary bonuse stock option franc nonvoting equity security show table head remuneration member execu nonexecutive member ofthe board ofdirec tive committee tor award share option december hold unvested senior manager member executive option award previous year committee additionally receive annual expense allowance swiss franc addition nonexecutive member respectivelythechiefexecutive officer receive board director step annual expense allowance swiss francsin receive remuneration totalling swiss franc members executive committee annual report corporate governance remuneration member executive committee cash payment chf annual salary annual salary annual salary bonus bonus bonus humer burn hunziker keller jkc knowle laube von prondzynski total pro rata period october december stock option nonvoting equity security ne genussscheine total remuneration pspvalue total nesawarde year remuneration threeyear psp programme cash stock stock option stock option stock option year option year psp value chf value chf value chf total number chf value chf humer burn hunziker keller jkc knowle laube von prondzynski total blackschole valuation describe section stock option pro rata period october december total receive expense allowance total roche nonvoting equity security ne swiss franc genussscheinunder term estab lishe option planthe exercise price ofthe option richard tlaube step executive show closing price roche nes committee december leave trading day prior roche annual media con company june richard laube ferenceall ofthe option show nontradable award special bonus million swiss franc option subject vest recognition successful completion period yearone vest period sale ofroche consumer health rch oftwo yearsand vest period ofthree year unvested option lapse compensa stock option tion member voluntarily leave company december members ofthe executive vested option exercise committee hold option show table limited period oftimeifthey tradablethe fair stock optionsall option show value ofthe option calculate date table issue roche employee stock issue base blackschole formula optionseach option entitle holder purchase deduct average twoyear vest annual report corporate governance stock option number option number option number option humer burn hunziker keller jkc knowle laube von prondzynski total exercise price chf expiry date allotment value option chf value base blackschole valuation minus pro rata period october december ing period exercise price expiry date roche connecta voluntary stock purchase allotment price show table stock planemployee opportunity buy roche optionsabovethe value ofthe option table nonvoting equity security ne genussscheine remuneration ofmember ofthe executive com equal annual mitteebstock optionsnonvote equity securi salary discountne purchase tie ne genussscheine total remuneration plan subject hold period base calculation method switzerland year time ofissue performance share plan indirect benefit member executive committee employer contribution member senior management social security scheme pension plan performance major impact roche ability groupwide employee stock purchase plan roche achieve corporate objective indi connect respect member executive vidual worldwide participate perfor committee show table indirect benefit mance share plan pspwhich establish indirect benefit pension fundsmgb ahvivalv roche connect chf chf chf humer burn hunziker keller jkc knowle laube von prondzynski total mgb stiftung der hoffmannla roche mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit ahvivalv swiss social security programme provide retirement disability unemployment benefit annual report corporate governance begin provision swiss francsthe distribution ofdividend total programme base salary billion swiss franc ne price apply time number ne reserve participantsthe actual comparisonthe average total shareholder return distribution security depend tsr peer set significantly low andtowhat extent investment roche securi result decline value tsr tie share ne outperform average roche security year return investment security issue peer high average tsr ofthe peer com setof company operate indus panie try year programme effect performance evaluate roche necessary provision basis ofmarket price dividend yield psp pro rata basis annual account year roche security share ne include dividend yield consis psp end december andin accor tently outperform average return deliver dance provision ofthis programmepar peer pharmaceutical diagnostic compa ticipate executive vest double ny roche rank second end number ne recognition contribu time roche market value increase tion company success addition billion swiss franc billion swiss participant elect place percentage francsequivalent growth billion ne block account aperiod offour year detailed information concern member executive committee present table remuneration ofmember ofthe executive com mitteebstock optionsnonvote equity securi tie nes genussscheine total remuneration annual report peer set abbott laboratories amgen astrazeneca aventis bayer becton dickinson bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck novartis pfizer sanofisynthlabo scheringplough takeda wyeth roche performance roche peer group average performance total shareholder return tsr value chf invest week january roche market capitalisation billion chf roche security chf nonvoting equity security ne share price translate constant chf exchange rate tsr stock price change plus dividendcorporate governance remuneration emolument loan note roche group consolidate financial corporate officer statement related party gottlieb keller take mortgage loan note financial statement ofroche hold swiss franc pension fund ltd additiona december hoffmannla roche ltd interest rate nonexecutive member ofthe board ofdirec pathe interest rate loan fix tor person closely associate hold december sharesthe members ofthe executive com mittee person closely associate pension total swiss franc pay hold share date executive committee member widow bonus total relationship group auditor statutory swiss franc pay auditor executive committee member previous year annual general meeting roche holding ltd april kpmg klynveld peat marwick otherwiseno additional remuneration pay goerdeler kpmg elect group audi current member executive com tor statutory auditor information mittee appointment group auditor date principal auditor take office high total remuneration find group auditor chairman board ceo franz statutory auditor participate audit cor humer member ofthe board mem porate governance committee meetingsthe audi ber executive committee high tor write oral report result total remuneration show table auditsthe audit corporate governance aboveinclude allocation ofthe awards committee oversee assess auditor threeyear performance share plan direct make recommendation board infor salary follow mation responsibility audit high total remuneration chf cash payment stock option value base blackschole formula minus performance share plan allocation year total value shareholding corporate governance committeesee article bylaw group auditor statutory directors andr hoffmann andreas oeri auditor participate meeting ofthe audit member founder family corporate governance committee closely associate belong share holder group pool voting rightsat end kpmg receive follow remuneration group hold share service group auditor statutory issue share follow fritz gerber retire auditor roche holding ltd roche ment board departure share financial company holder group april andr hoffmann take role pool spokesman detailed httpwwwrochecomhomecompany information group present comgovcomgovbylawshtm annual report corporate governance millions chf additional information relate corporate auditing service governance auditrelated service tax consultancy service group structure shareholder total roche operate business organise divisionspharmaceutical diagnostic group auditor statutory auditor pharmaceutical division comprise elect year annual general meeting business segment roche prescriptiongenentech prescription chugai prescription sale ernst young ltd receive follow remuner consumer health otc business result ation service auditor ofgenentech inthe transfer ofroche otc business bayer chugai december chugais otc business lion corporation december millions chf diagnostic division consist offive business genentech chugai audit area diabetes care near patient testing cen consulting service provide tralize diagnostic molecular diagnostic genentech chugai apply science business activity carry total group subsidiary associate companiessignificant subsidiary associate company list note roche group consolidate financial statement sub sidiarie associate companiespage major shareholder list note roche group consolidated financial state ment equityand relate partiespage note financial statement ofroche holding ltd andr hoffmann andreas oeri serve board ofdirector representative ofthe share holder pool voting right receive remuneration set table remuneration member board directorsaboveno relationship exist shareholder pool voting right crossshareholding capital structure information roche capital structure pro vided note financial statement roche holding ltd additional detail contain article incorporation roche holding ltd change equity detail note financial statement roche holding ltd httpwwwrochecomhomecompany comgovcomgovartihtm annual report corporate governance company share capital board director establish system swiss franc divide fully pay control oversee audit bearer share nominal value swiss franc corporate governance committee consist limitation transfer follow element share share maximum voting report financial operating risk rightsupon depositshare vote internal audits restriction compliance officer authorise conditional capital safety environment department addition ne issue corporate sustainability committee bearer formthey form share scientific ethic advisory group seag capital confer vote rightseach nes con issue relate genetic genetic engi fer right share participate neering establish available earning liquidation proceed year blackout period impose follow repayment share capitalroche senior employee prohibit ne provision secure claim trading company stock follow right pertain thereto describe ofthe blackout period effect article ofincorporation ofroche holding ltd january february information debt instrument april april issue outstanding bond july july find note roche group consoli october october date financial statement debt blackout period change chairman additional information employee stock ofthe board ofdirector ifcircumstance warrant option find note board ofdirector hold total offive meeting roche group consolidated financial statement board committee meet follow employee stock option equity com pensation benefit presidium ofthe board ofdirectorsnomi roche issue option apart nation committeefive meeting award employee issue audit corporate governance commit connection debt instrument teefour meeting option award employee finance investment committee debt instrument issue meeting effect roche share capital remuneration committeefour meeting management contract fall board director executive committee mean ofsubsection ofthe swx information member board corporate governance directive director include year elect year term end participatory right shareholder executive committee list page participatory right shareholder fully curricula vitae information define roche article incorporation board executive committee member roche share issue bearer include information board membership restriction admission annual general available internet meetingswith exception share ofthe nonexecutive member ofthe board director member executive committee roche group sub httpwwwrochecomhomecompany sidiarie financial year precede comgovhtm current reporting period httpwwwrochecomhomecompany internal organisation board direc comgovcomgovbylawshtm tor division ofauthority responsibil httpwwwrochecomhomecompany ities board management comgovcomgovartihtm govern bylaw annual report corporate governance deposit specify period date information policy meeting admittance card provide article incorpo issue shareholder provide ration corporate notice publish article incorporation share swiss official gazette commerce schwei holder elect represent zerische handelsamtsblatt daily shareholder annual general meeting newspaper designate board director article incorporation contain restriction basl zeitungfinanz und wirtschaftlagefile exercise ofvote rightsand quo tempsneue zrcher zeitung rum requirement stipulate roche report halfyear fullyear result ofthe article ofincorporationshare inbusiness report publish print online holder represent share nominal value format medium event addition swiss franc request place thirdquarter sale figure publish ment item business agenda year april octobercurrent date ofpubli annual general meeting cation available english german later day date ofthe meeting internet relevant information documentsinclud change control defensive measure ing medium release presentation article incorporation contain provi analyst investor conference avail sion mandatory bid ruleswiss law apply able english german internet changeofcontrol clause publication order email component remuneration base roche fax telephone baselwebmasterrochecom ne terminate event ofan acqui tel fax sition vest period restriction pre contact address investor relation exist award removedso hoffmannla roche ltd investor relation option immediately exercise corporate finance basel switzerland tel fax additional informationincluding detail spe cific contact personsis available internet nonapplicabilitynegative disclosure expressly note information con taine mention nonapplicable omission construe negative declara tion according requirement swx corporate governance directive include commentary httpwwwrochecomhomecompany comgovcomgovartihtm httpwwwrochecomhomemediamedeventshtm httpwwwrochecomhomeinvestorsinvcontacthtm annual report corporate governance compliance officer compliance officer commit ensure roche corporate principle consistently comply roche group serve contact person shareholder employee customer supplier general public issue relate implementation compliance principle employee party aware violation roche corporate principle bring attention manager supervisor report compliance officer andrea greuter direct phone number disclosure treat confidentialemployee disclosure penalise company sobut immune prosecution legal violation compliance officer sub mit regular report audit corporate governance committee annual report make diabete easy live number people diabetes rise sharply recent year accord estimate reach million situation describe global epidemic diabete associate complication include blindness heart attack stroke kidney damage limb amputation problem prevent improve regular blood glucose monitor right insulin regimen mean health system patient stand benefit thirty year ago idea people diabete mon itoring glucose go daily life unthinkable norm roche diagnostic major hand bring change today small easytouse glucose meter like accuchek compact match pre cision accuracy laboratory late software personal digital assistant make possible manage glucose insulin datum story end want life simple safe people diabete example find way measure blood glucose blood sample devel ope insulin pump allow continuous insulin delivery longterm goal create artificial pancrea huge step forward fight diabetes monitor monitoring device people dia bete benefit compact hightech self monitor device real patient take anticoagulant need quick reliable information coagulation status specific diagnostic test system play vitalrole monitoring type therapy example help doctor track patient response antihiv therapy necessary right treatment change right time annual report selfmonitore give independence security short well quality life gudrun schindler live schwbische alb region germanyadvise people diabete know talk year check blood glucose time day roche accuchek systems predisposition early detecion prevention diagnosis therapy monitor annual report finance brief net income millions chf net income continue business exceptional item millions chf ebitda continue business million chf net liquidity yearend millions chf debt yearend millions chf stock price nonvoting equity security genussschein yearend chf exclude gain labcorp transaction annual report finance roche finance contribute significantly excellent group result support divestment otc business create condition balance financial income billion swiss franc proceed otc divestment cover billion swiss franc cost acquisition igen debt reduce billion swiss franc result significantly low interest expense continue reduce risk exposure financial investment foreign exchange transaction finance activity couple strong cash generation pharmaceutical diagnostic evidence ebitda billion swiss franc lead increase group net liquidity billion swiss franc billion swiss franc ratio equity minority interest total asset improve erich hunzikerchieffinancial officer annual report key figure key figure millions chf roche group continue businessesa change change chf chf sale research development ebitdab operating profit exceptional item operating profit financial income net income exceptional itemsc net income epsdbefore exceptional item chf epsdin chf research development sale ebitda sale operating profit exceptional item sale effective tax rate net income sale roche group roche group december december net liquidity total asset equity minority interest debt equity ratioe debtequity ratiof continue business include pharmaceutical diagnostic business treasury corporate activity consumer health otc vitamin fine chemical report discontinue business ebitda earning exceptional item interest financial income tax depreciation amortisation include impairment correspond operate profit exceptional item depreciation amortisation include impairment net income exceptional item ep exceptional item calculate show eps earning share nonvoting equity security dilute equity ratio equity minority interest percentage total asset debtequity ratio debt percentage equity include minority interest local currency annual report finance brief market sale growth sale core business local currency strong growth highmargin product business area improve profitability pharmaceutical diagnostic operate profit continue business exceptional item increase local currency pharmaceutical operating profit margin exceptional item increase percentage point diagnostic operate profit margin exceptional item increase percentage point continue high investment billion swiss franc funding inlicense deal selective disposal noncore product divestment otc business sale roche consumer health bayer sale chugais otc business lion corporation bayer deal include pharmaceutical production facility reduce asset level transaction realise total pretax gain billion swiss franc deal cash transaction completion igen acquisition acquisition complete february billion swiss franc strengthen access diagnostic immunochemistry sector continue debt restructure restructure highinterest debt instrument retire debt decrease billion swiss franc interest expense reduce million swiss franc exceptional pretax income million swiss franc bond conversion redemption reduce financial risk risk exposure financial asset foreign exchange transaction reduce increase net liquidity increase billion swiss franc billion swiss franc increase net income increase net income billion swiss franc increase net income continue business exceptional item billion swiss franc annual report table content finance roche group financial review roche group consolidated financial statement note roche group consolidated financial statement report group auditor multiyear overview supplementary net income ep information roche security roche holding ltd basel financial statement note financial statement appropriation available earning report statutory auditor annual report financial review operating result continue business exceptional item sale increase sale core business gain market share roche group record sale billion swiss franc continue business represent increase local currency swiss franc growth division ahead respective market growth pharmaceutical drive roche successful oncology franchise include firsttime sale avastin tarceva million swiss franc respectively strong growth virology franchise include pegasyscopegus transplantation franchise product cellcept valcytecymevene diagnostic major driver diabetes care molecular diagnostic immunodiagnostic sale grow ahead market rate sale continue businessesin millions chf change change chf local currency pharmaceutical roche prescription genentech prescription chugai prescription diagnostic sale continue business divisional result operate profit exceptional item increase local currency swiss franc billion swiss franc pharmaceutical increase operate profit margin increase percentage point diagnostic improve percentage point achieve strong sale growth increase income product divestment cover additional spending newly launch product upcoming launch investment development pipeline divisional result continue business exceptional item millions chf operate operating profit divisional ebitda profit exceptional sale exceptional item party ebitda sale item sale pharmaceutical roche prescription genentech prescription chugai prescription diagnostic group total continue business pharmaceutical roche prescription genentech prescription chugai prescription diagnostic group total continue business annual report financial review pharmaceutical operating profit increase local currency swiss franc billion swiss franc represent sale compare ebitda show similarly strong result increase billion swiss franc rise local currency ebitda margin increase high profitability drive largely local currency sale growth underproportional growth marketing distribution administration amortisation intangible asset investment research development grow local currency reach billion swiss franc sale include inlicense investment million swiss franc fund gain product disposal million swiss franc roche prescription operate profit margin roche prescription business increase percentage point marketing distribution amortisation intangible asset grow underproportionately investment research development grow significantly fast sale drive strong development pipeline inlicense investment royalty expense license product increase increase largely fund selective disposal noncore product genentech prescription business achieve strong sale profit growth operate profit upby local currency swiss franc operating profit margin increase despite additional spending marketing promotional program support commercial pipeline product primarily avastin tarceva raptiva xolair mabtherarituxan herceptin additional expense incur expansion infrastructure necessary support sale growth charge million swiss franc relate discontinuation commercialisation nutropin depot chugai prescriptionthis business post operate profit million swiss franc operating profit margin reach compare strong performance result sale growth second halfyear operating profitability significantly low comparative period drive restructuring expense early retirement programme impact show significantly high operating profitability second half year basically japanese pattern relatively low sale quarter follow high fourthquarter sale previous year diagnostic operating profit increase billion increase operating margin percentage point ebitda increase billion swiss franc result ebitda margin main driver result sale growth addition high royalty income broadly equivalent net effect result income legal settlement product disposal cost disetronic restructuring charge additional amortisation expense intangible asset arise igen acquisition basically equivalent royalty expense previously pay igen include cost corporate headquarters annual report financial review group operating result operate profit continue business exceptional item millions chf change change chf local currency sale cost sale gross profit marketing distribution research development administration amortisation intangible asset operating income operate expense operating profit exceptional item continue business gross profit gross profit margin improve percentage point reflect growth high margin product effect continue productivity improvement marketing distribution increase support newly launch product pegasyscopegus fuzeon xolair raptiva avastin tarceva marketing activity grow diagnostic business marketing distribution percentage sale decrease percentage point increase expenditure sale growth research development increase mainly significantly increase activity support strong development pipeline include inlicense optin compound research development cost percentage sale increase percentage point compare forpharmaceutical account group research development expense increase percentage point sale administrationthe increase alignment infrastructure genentech reflect continue growth business increase legal expense amortisation intangible asset increase intangible asset acquire disetronic igen acquisition result include million swiss franc igen represent month acquisition year charge million swiss franc disetronic result include month amortisation operating income increase product divestment soriatane gain product divestment total million swiss franc compare million swiss franc gain fund increase level inlicense activity royalty income increase operate expensethis increase basically high royalty expense inlicense product mabtherarituxan xolair addition million swiss franc charge intangible asset impairment particular result genentech decision discontinue commercialisation nutropin depot annual report financial review discontinue operation discontinue operationsin million chf sale operating profit exceptional item otc businesssale nonprescription medicine increase swiss franc million swiss franc operating profit exceptional item million swiss franc include restructure cost million swiss franc vitamin fine chemical business effective september receive final regulatory approval group complete sale global vitamin fine chemical business dutch company dsm result roche group include result vitamin fine chemical business september exceptional item nonoperate result exceptional item nonoperate resultsin million chf continue discontinuing business business group operating profit exceptional item amortisation goodwill major legal case change group organisation operate profit income associate company financial income exceptional income bond conversion redemption profit taxis income taxis profit taxis minority interest net income earning share nonvoting equity security basic chf diluted chf amortisation goodwill goodwill amortisation disetronic igen acquisition million swiss franc versus million swiss franc million swiss franc respectively roche continue amortise goodwill include hold genentech presents exceptional item view international financial reporting standard change implement annual report financial review major legal casesthere significant development additional income expense record change group organisationin group announce sale roche consumer health include roche prescription manufacturing site bayer sale substantially complete yearend cover majority site business involve addition chugai complete sale otc business japan lion corporation total pretax gain sale billion swiss franc include impairment restructure charge roche prescription business totalling million swiss franc result include loss sale vitamin fine chemical business totalling million swiss franc operating profit overall operating profit increase billion swiss franc local currency follow billion swiss franc realise gain sale consumer health otc business compare billion swiss franc loss disposal vitamin fine chemical business exceptional item operating profit increase local currency billion swiss franc income associate company result associate significant financial income financial income show improvement compare net income equity security million swiss franc compare net expense million swiss franc comparative result include impairment loss million swiss franc compare million swiss franc ongoing income equity debt security decrease low holding total interest expense million swiss franc reduction retirement debt instrument refinance obligation cover convertible debt instrument carry netforeign exchange gain million swiss franc compare million swiss franc follow reduction foreign exchange exposure analysis financial income give note consolidated financial statement exceptional income bond conversion redemption continue refinance restructure group debt lyon lyon iii note call redemption group redeem chameleon bond public tender lyon redemption outstanding note call conversion genentech share holder addition group reassess likely future cash outflow lyon note conclude appropriate consider date july probable date cash flow accordingly effective interest rate method group record pretax expense million swiss franc allow accreted debt value meet issue price plus accrue original issue discount oid july net pretax gain million swiss franc arise transaction primarily group partial disposal interest genentech conversion lyon note material impact present exceptional item income statement income taxis group continue business effective tax rate compare rate include recognition certain previously unrecognised tax loss local effect offset negative effect tax rate conversion redemption bond relatively high total group effective tax rate result cause impairment charge vitamin fine chemical business reconciliation effective tax rate give note consolidated financial statement minority interest income applicable minority increase continually improve profit contribution genentech chugai million swiss franc relate genentech million swiss franc chugai annual report financial review net incomethe group increase net income follow improve operating result exceptional gain tax minority interest billion swiss franc otc divestment billion swiss franc bond conversion redemption exclude exceptional item net income continue business basis increase million swiss franc cash flow net liquidity cash flow statementin million chf cash generate business operation increase decrease work capital income cost major legal case receive pay operating cash flow operating activity income taxis income taxis pay activity operating activity invest activity financing activity net effect currency translation cash increase decrease cash term agreement bayer majority proceed divestment consumer health otc business amount million swiss franc transfer group january amount include table note consolidated financial statement operate cash flow group business operation continue strong cash generation billion swiss franc drive continued growth ebitda income taxis pay normal level compare include large income tax receivables recover tax authority cash flow otc business include figure ebitda business million swiss franc million swiss franc cash flow vitamin fine chemical business include figure ebitda business million swiss franc invest cash flowsthe large invest cash flow billion swiss franc pay respect igen acquisition invest cash flow include expenditure property plant equipment large net cash inflow sale group portfolio marketable security order fund repayment debt instrument vitamin case payment disposal otc business increase cash billion swiss franc main proceed billion swiss franc receive bayer january finance cash flow significant financing cash flow relate dividend payment redemption debt instrument dividend pay billion swiss franc billion swiss franc cash redemption debt instrument billion swiss franc lyon iii note chameleon bond compare billion swiss franc bullet bond lyon note redemption conversion lyon note cash impact million swiss franc debt obligation entirely settle delivery genentech share cash flow include billion swiss franc proceed issue group european medium term note programme outflow billion swiss franc refinance instrument cover convertible debt obligation annual report financial review net liquidityin millions chf december december change cash marketable security receivable bayer group collect january financial longterm asset restrict cash derivative financial instrument net equity instrument financial asset longterm debt shortterm debt total debt net liquidity net liquidity increase main driver strong cash inflow operating activity billion swiss franc inflow billion swiss franc divestment consumer health otc business cover outflow billion swiss franc acquisition igen lyon note conversion reduce debt increase net liquidity billion swiss franc lyon iii chameleon transaction affect debt cash little effect net liquidity balance sheet balance sheetin millions chf december december change longterm asset current asset total asset equity minority interest noncurrent liability current liability total equity minority interest liabilitie longterm asset igen acquisition increase goodwill intangible asset billion swiss franc thesale otc business reduce longterm asset billion swiss franc fall usdollar swiss franc end reduce longterm asset swiss franc term group production facility intangible asset dollar denominate current asset current asset increase billion swiss franc proceed sale otc business cash generate operation current asset decrease billion swiss franc cash pay igen billion swiss franc cash payment dividend billion swiss franc cash redemption lyon iii note partial redemption chameleon bond sale otc business reduce current asset mainly inventory trade receivable billion swiss franc equity significant movement net income billion swiss franc dividend payment billion swiss franc annual report financial review minority interest conversion lyon note lead increase minority ownership genentech swiss franc term offset fall dollar swiss franc noncurrent liability major movement sumo bonds book value billion swiss franc march classify shortterm debt partial redemption chameleon bond reduce longterm debt billion swiss franc movement dollar rate reduce swiss franc carry value group dollar denominate debt instrument current liabilitiesthe conversion redemption lyon lyon iii note reduce shortterm debt billion swiss franc partly compensate reclassification sumo bond longterm debt strong financial condition group remain solidly finance equity include minority interest represent total asset total asset finance longterm international financial reporting standard roche group international financial reporting standard ifrs report consolidated result late international accounting standard board iasb publish number new revise standard group implement effective january fully discuss note consolidated financial statement change group expect significant impact describe equity compensation plan fair value equity compensation plan award employee estimate grant date record expense vest period change apply retrospectively certain transitional restriction base initial work carry apply transitional restriction group estimate impact operating income net income approximately million swiss franc million swiss franc respectively transitional rule indicative future impact goodwill amortisation effective january amortisation goodwill cease goodwill continue test impairment standard require prospective application standard apply goodwill amortisation expense million swiss franc record net income million swiss franc high recognition intangible asset revise standard intangible asset business combination typically result intangible asset recognise acquisition inlicense collaboration alliance previously financial instrument group fully apply exist ias financial instrument change standard financial instrument expect major effect equity minority interest minority interest include group equity separate category balance sheet increase group equity million swiss franc effective january group expect new revise standard significant effect group result financial position annual report financial review financial risk valueatrisk earningsatrisk analysis tool valueatrisk var calculation indicate range value respective asset liability fluctuate certain probability certain time period hold period var measure statistical measure implicitly assume value change recent past indicative value change future market shock include calculation recently observe group conduct additional stress testing possibility consideration group use statistically relevant observation period apply hold period reflect time period require change respective risk exposure deem appropriate long hold period probability high value change increase var measure earningsatrisk ear equivalent var methodology potential value change indicate potential change profit loss certain probability certain time period constraint limitation apply methodology var ear figure interest rate risk measure historical simulation approach historical scenario represent price rate change individual instrument specific day period past financial instrument fully revalue valuation model total change value earning determine var figure base delta normal approach assume normal market condition var ear calculation base confidence level hold period day group predict future market movement var ear figure give represent actual loss expect incur financial asset liability possible bad loss period state consider effect favourable change market rate foreign exchange risk group operate world expose movement foreign currency affect net income financial position express swiss franc growth continue business local local currency currency chf chf sale operating profit exceptional item exchange rate swiss franc december average december average usd eur gbp jpy annual report financial review average dollar considerably weak swiss franc euro slightly strong swiss franc total negative currency effect sale growth continue business operate profit growth percentage point absolute term sensitivity group sale continue business change dollar swiss franc swiss franc average approximately million swiss franc correspond sensitivity euro yen approximately million swiss franc million swiss franc respectively group monitor net currency exposure appropriate enter transaction aim preserve value asset commitment anticipate transaction group use forward contract swap foreign currency option optimise certain anticipate foreign exchange revenue cash flow financing transaction group pursue strategy continuously lockin favourable development foreign exchange rate enter derivative contract reduce exposure potential future move foreign exchange rate foreign exchange transaction var remain low level foreign exchange risk millions chf december december change var monetary position interest rate risk interest rate risk arise movement interest rate adverse effect group net income financial position change interest rate cause variation interest income expense interestbeare asset liability addition affect market value certain financial asset liability instrument appropriate group use financial derivative swap option manage interest rate risk group reduce outstanding debt order achieve well match term structure asset liability group swap sizeable remain debt float interest rate consequence exposure potential change interest rate decrease interest rate var measure potential change net market value interest rate sensitive asset liability decline comparatively small risk repricing refinancing contain reasonable level earningsatrisk ear slightly increase mainly result generally high interest rate level allow room downward change interest rate interest rate risksin millions chf december december change var instrument sensitive interest rate ear instrument sensitive interest rate market risk financial asset change market value cash marketable security affect net income financial position group market risk arise movement stock price interest rate foreign exchange rate annual report financial review equity allocation group portfolio cash marketable security reduce billion swiss franc billion swiss franc december currency allocation fund change extent small shift group asset allocation result slightly increase var position compare year calculate var figure exclude position genentech chugai run treasury operation independently market risk financial asset millions chf december december change var cash marketable security annual report roche group consolidate financial statement reference number indicate corresponding note consolidated financial statement consolidated income statement year end december million chf continue discontinuing business business group sale cost sale gross profit marketing distribution research development administration amortisation intangible asset operating income operating expense operate profit exceptional item amortisation goodwill major legal case change group organisation operate profit income associate company financial income exceptional income bond conversion redemption profit taxis income taxis profit taxis minority interest net income earning share nonvoting equity security basic chf diluted chf annual report roche group consolidate financial statement consolidated income statement year end december million chf continue discontinuing business business group sale cost sale gross profit marketing distribution research development administration amortisation intangible asset operating income operating expense operate profit exceptional item amortisation goodwill major legal case change group organisation operate profit income associate company financial income profit taxis income taxis profit taxis minority interest net income earning share nonvoting equity security basic chf diluted chf annual report roche group consolidate financial statement consolidate balance sheetin millions chf december december longterm asset property plant equipment goodwill intangible asset investment associate company financial longterm asset longterm asset defer income tax asset postemployment benefit total longterm asset current asset inventory account receivable current income tax asset current asset marketable security receivable bayer group collect january cash cash equivalent total current asset total asset equity share capital nonvoting equity security genussscheine equity instrument retain earning fair value reserve total equity minority interest noncurrent liability longterm debt defer income tax liability postemployment benefit provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable accrue current liability total current liability total equity minority interest liability pro memoria nonvoting equity securities nominal value note annual report roche group consolidate financial statement consolidate statement change equityin million chf year end december share capital balance january december nonvoting equity security genussscheine balance january december equity instruments balance january acquisition disetronic conversion helveticus bond refinance instrument cover convertible debt obligation movement year balance december retain earning balance january net income dividend pay balance december fair value reserve balance january change fair value attributable availableforsale investment qualify cash flow hedge fair value gain loss attributable availableforsale investment qualify cash flow hedge recognise income statement fair value gain loss attributable qualify cash flow hedge transfer adjust initial measurement acquisition cost asset carry hedge asset liability defer income taxis minority interest currency translation gain loss balance december total equity december pro memoria nonvoting equity securities nominal value note annual report roche group consolidate financial statement consolidate cash flow statementin million chf year end december cash flow operating activity cash generate operation increase decrease work capital vitamin case payment igen litigation genentech legal case payment define benefit postemployment plan utilisation restructure provision utilisation provision operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset disposal product acquisition subsidiary associate company divestment subsidiary associate company interest dividend receive sale marketable security purchase marketable security invest cash flow total cash flow invest activity cash flow financing activity proceed issue longterm debt instrument repayment longterm debt instrument increase decrease longterm debt refinance instrument cover convertible debt obligation transaction equity instrument increase decrease shortterm borrowing interest dividend pay genentech chugai stock repurchase exercise employee stock option genentech finance cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year term agreement bayer majority proceed divestment consumer health otc business amount million swiss franc transfer group january amount include table note annual report note roche group consolidate financial statement reference number indicate corresponding note consolidated financial statement summary significant accounting policy basis preparation consolidate financial statement consolidate financial statement roche group prepare accordance international financial reporting standard ifrs prepare historical cost convention disclose accounting policy certain item include derivative availableforsale investment show fair value approve issue board director january subject approval shareholder february preparation consolidated financial statement require management estimate assumption affect report amount revenue expense asset liability disclosure contingent liability date financial statement future estimate assumption base management good judgement date financial statement deviate actual circumstance original estimate assumption modify appropriate year circumstance change necessary comparative reclassify extend previously report result account presentational change consolidation policy financial statement consolidate financial statement roche holding ltd company register switzerland subsidiary group subsidiary company control directly indirectly roche holding ltd control define power govern financial operating policy enterprise obtain benefit activity control normally evidence roche holding ltd own directly indirectly vote right potential voting right company share capital special purpose entity consolidate substance relationship special purpose entity control group company acquire year consolidated date control transfer group subsidiary divest include date control pass group company acquire exclusively resold month consolidate classified financial asset heldfortrade carry fair value intercompany balance transaction result unrealised income eliminate investment associate company account equity method company group exercise power exercise significant influence control normally evidence group own voting right potential voting right company balance transaction associate company result unrealised income eliminate extent group interest associate company interest joint venture report linebyline proportionate consolidation method segment report group primary format segment report business segment secondary format geographical segment risk return group operation primarily determine different product group produce geographical location group operation reflect group divisional management organisational structure group internal financial reporting system group division pharmaceutical diagnostic disposal september group division vitamin fine chemical pharmaceutical division subdivision roche prescription genentech prescription chugai prescription subdivision separate management reporting structure pharmaceutical division consider separately reportable segment consumer health otc business separately reportable business segment present discontinue business certain corporate activity reasonably allocate reportable segment cost corporate headquarters report annual report note roche group consolidate financial statement group geographical segment determine geographical location similarity economic environment transfer price business segment set arm length basis divisional asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory segment asset liability consist asset liability reasonably attribute report business segment include pension assetsliabilitie provision non segment asset liability mainly include current defer income tax balance financial asset liability principally cash marketable security investment debt capital expenditure comprise addition goodwill intangible asset addition property plant equipment include arise acquisition foreign currency translation group company use local currency measurement currency certain group company use currency dollar swiss franc euros measurement currency usefully represent result financial position company give local economic condition circumstance local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity defer equity consolidation asset liability group company measurement currency swiss franc foreign entity translate swiss franc yearend rate exchange sale cost expense net income cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly equity divestment foreign entity identify cumulative currency translation difference relate foreign entity recognise income gain loss divestment revenue cost sale sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude sale value add taxis revenue sale product recognise transfer customer significant risk reward usually shipment trade discount cash discount volume rebate record accrual basis consistent recognition relate sale revenue record earn service perform cost sale include correspond direct production cost relate production overhead good sell service render startup cost validation achievement normal production capacity expense incur royalty income recognise accrual basis accordance economic substance agreement report operate income research development research cost charge income incur development cost capitalise intangible asset particular probable future economic benefit flow group intangible asset amortise straightline basis period expect benefit review impairment balance sheet date development cost charge income incur criterion recognition asset met inlicense milestone upfront receipt payment certain group company notably genentech receive thirdpartie upfront milestone similar nonrefundable payment relate sale licensing product technology revenue associate performance milestone recognise base achievement milestone define respective agreement revenue nonrefundable upfront payment licence fee initially report deferred income recognise income earn period development collaboration manufacturing obligation payment group company party associate company annual report note roche group consolidate financial statement item charge income research development cost probable future economic benefit flow group normally evidence regulatory approval case capitalise development cost amortise describe practice mean license milestone payment pharmaceutical product expense incur case gain regulatory approval receipt payment consolidate subsidiary genentech chugai roche group subsidiary eliminate consolidation extent impact minority interest employee benefit wage salary social security contribution pay annual leave sick leave bonus nonmonetary benefit accrue year associate service render employee group group provide longterm employee benefit cost accrue match rendering service employee concerned group operate number define benefit define contribution plan world cost year define benefit plan determine project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth longterm expect rate return plan asset discount rate base market yield highquality corporate bond country concern difference assumption actual experience effect change actuarial assumption allocate estimate average remain work live employee difference exceed define corridor past service cost allocate average period benefit vested pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan recognition pension asset limit net total unrecognised actuarial loss past service cost present value future refund plan reduction future contribution plan group contribution define contribution plan charge income statement year relate group operate equity compensation plan include separate plan genentech chugai fix plan roche option plan equivalent plan genentech chugai expense recognise date issue exercise price greater equal fair value underlie equity instrument date issue subsequent cash flow exercise vest grant record equity case genentech chugai plan balance sheet minority interest performance relate variable plan roche performance share plan stock appreciation right expense accrue vest period difference exercise price fair value underlie equity instrument taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include operating expense financial income accord nature liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable intention remit earning defer income tax asset liability recognise temporary difference tax basis asset liability carry amount financial statement defer income tax asset relate carryforward unused tax loss recognise extent probable future taxable profit available unused tax loss utilise current defer income tax asset liability offset income taxis levy taxation authority legally enforceable right offset deferred income taxis determine base currently enact tax rate applicable tax jurisdiction group operate annual report note roche group consolidate financial statement property plant equipment property plant equipment initially record cost purchase construction depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow building land improvement year machinery equipment year office equipment year motor vehicle year estimate useful life asset regularly review necessary future depreciation charge accelerate investment grant similar assistance project initially record deferred income noncurrent liability subsequently recognise income useful life relate asset repair maintenance cost recognise expense incur borrowing cost capitalise lease lease property plant equipment group substantially risk reward ownership classified finance lease finance lease capitalise start lease fair value present value minimum lease payment low rental obligation net finance charge include debt asset acquire finance lease depreciate accordance group policy property plant equipment interest element lease payment charge income lease term base effective interest rate method lease substantially risk reward ownership transfer group classify operating lease payment operating lease charge income straightline basis period lease business combination goodwill business combination account purchase method accounting cost acquisition cash pay plus fair value date exchange purchase consideration give exchange control net asset acquire company cost acquisition include directly attributable incidental cost acquire identifiable asset liability initially recognise fair value group acquire ownership acquire company asset liability recognise fair value extent group interest minority interest record minoritys proportion preacquisition carry amount acquire asset liability goodwill record surplus cost acquisition group interest fair value identifiable net asset acquire goodwill fair value adjustment record asset liability acquire company record local currency company goodwill amortise useful life straightline basis estimate useful life goodwill year goodwill arise investment associate company surplus cost investment group share fair value net identifiable asset goodwill record investment associate company amortisation include income associate company intangible asset patent licence trademark intangible asset initially record cost asset acquire business combination fair value allocate acquisition accounting acquire business combination initial fair value cost intangible asset amortise useful life straightline basis estimate useful life low legal duration economic useful life exceed year estimate useful life asset regularly review necessary future amortisation charge accelerate impairment property plant equipment intangible asset evidence asset impair recoverable asset calculate impairment assessment carry recoverable asset high net selling price value use carrying carry reduce recoverable annual report note roche group consolidated financial statement value reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm pretax interest rate impairment loss arise useful life asset question review necessary future depreciationamortisation charge accelerate impairment financial asset discuss financial asset policy inventory inventory state low cost net realisable value cost finish good work process comprise raw material direct labour directly attributable cost overhead base normal capacity production facility borrowing cost include cost determine weighted average method net realisable value estimate selling price cost completion selling expense account receivable account receivable carry original invoice allowance doubtful account allowance record difference carry recoverable objective evidence group able collect amount cash cash equivalent cash cash equivalent comprise cash hand time current balance bank similar institution readily convertible know amount cash subject insignificant risk change value maturity month date acquisition definition cash flow statement equity instrument group holding equity instrument record deduction equity original cost acquisition consideration receive subsequent resale equity instrument movement report change equity instrument acquire primarily meet obligation arise respect certain group debt instrument debt instrument debt instrument initially report cost proceed receive net transaction cost subsequently report amortise cost effective interest method extent debt instrument hedge qualify fair value hedge carry value hedge item adjust fair value movement attributable risk hedge discount net proceed receive principal value redemption amortise duration debt instrument recognise interest expense income statement issue convertible debt instrument cost liability portion initially calculate market interest rate equivalent nonconvertible instrument remainder net proceed allocate equity conversion option report equity defer income tax liability equity conversion option share consolidated subsidiary portion net proceed attributable option record minority interest liability element subsequently report amortise cost amortisation debt discount release defer tax liability recognise income statement duration debt instrument value equity conversion option record equity change future period limited conversion prefer stock substance financial liability equity instrument classified longterm debt balance sheet relate dividend payment treat interest expense provision provision recognise legal constructive obligation incur probably lead outflow resource reasonably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise take account foreign annual report note roche group consolidate financial statement currency effect arise translation measurement currency swiss franc time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value financial asset liability instrument exchange knowledgeable willing party arm length transaction determine reference quote market price use establish estimation technique option pricing model estimate discount value cash flow fair value balance sheet date approximately line report carry value specifically mention note consolidated financial statement financial asset financial asset principally investment include marketable security classify heldfor trade availableforsale heldtomaturity originate group heldfortrade financial asset acquire principally generate profit shortterm fluctuation price heldtomaturity financial asset security fix maturity group intent ability hold maturity financial asset originate group loan longterm financial asset create group acquire issuer primary market financial asset consider availableforsale financial asset initially record cost include transaction cost purchase sale recognise settlement date heldfortrade financial asset subsequently carry fair value change fair value record financial income period arise heldtomaturity financial asset subsequently carry amortise cost effective interest rate method availableforsale financial asset subsequently carry fair value unrealise change fair value record equity availableforsale financial asset sell impair dispose cumulative gain loss previously recognise equity include financial income current period financial asset originate group subsequently carry amortise cost financial asset assess possible impairment balance sheet date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty availableforsale financial asset market value original cost net previous impairment sustain sixmonth period consider impaired decrease market price original cost net previous impairment sustained sixmonth period consider objective evidence impairment movement fair value record equity objective evidence impairment asset sell dispose financial asset carry amortise cost impairment charge difference carry value recoverable calculate estimate future cash flow discount original effective interest rate availableforsale financial asset impairment charge currently carry equity difference original cost net previous impairment fair value derivative derivative financial instrument initially record cost include transaction cost derivative subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record financial income period arise embed derivative recognise separately closely related host contract hedging purpose hedge accounting hedging relationship type fair value hedge hedge particular risk change fair value recognise asset liability cash flow hedge hedge particular risk change time future cash flow hedge net investment foreign entity hedge particular risk change carry value net asset foreign entity annual report note roche group consolidated financial statement qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship particular derivative report fair value change fair value include financial income qualify fair value hedge hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income qualify cash flow hedge hedge instrument record fair value portion change fair value effective hedge include equity remain ineffective portion report financial income hedge relationship hedge firm commitment highly probable forecast transaction cumulative change fair value hedge instrument record equity include initial carrying value asset liability time recognise qualify cash flow hedge cumulative change fair value hedge instrument record equity include financial income time forecast transaction affect net income qualifying hedge net investment foreign entity hedge instrument record fair value portion change fair value effective hedge include equity remain ineffective portion record financial income hedge instrument derivative equity case entity dispose cumulative change fair value hedge instrument record equity include financial income time disposal change accounting policy significant change accounting policy period present international financial reporting standard revise new standard interpretation effective january asignificant effect group financial statement late international accounting standard board iasb publish revise version ia financial instrument disclosure presentation revise version ia financial instrument recognition measurement improvement international accounting standard make change exist standard quarter iasb publish ifrs sharebase payment ifrs business combination ifrs insurance contract ifrs noncurrent asset hold sale discontinue operation revise version ias impairment asset ias intangible asset amendment ias group adopt effective january group estimate significant effect group result come implementation ifrs ifrs ifrs sharebase payment matter new standard require fair value equity compensation plan award employee estimate grant date record expense vest period currently plan equitysettle record equity case genentech chugai plan balance sheet minority interest standard require retrospective application certain transitional restriction base initial work carry apply transitional restriction group estimate pretax expense approximately million swiss franc million swiss franc relate genentechs equity compensation plan seenote million swiss franc relate roche option plan note impact transitional arrangement indicative future expense plan information group equity compensation plan give note new standard affect group effective tax rate defer tax record base expect tax benefit arise vested award current equity price input calculation defer tax benefit record particular period sensitive current equity price pretax expense fix reference equity price grant date sensitive current annual report note roche group consolidate financial statement equity price impact income statement defer tax benefit cap reference ifrspretax expense excess recognise directly equity base initial work carry apply transitional restriction group estimate tax benefit approximately million swiss franc aftertax additional expense million swiss franc million swiss franc attributable minority leave estimate impact net income million swiss franc ifrs business combination matter new standard require amortisation goodwill cease date implementation goodwill continue test impairment standard require prospective application standard apply goodwill amortisation expense million swiss franc record additional impairment necessary inaddition ia revise intangible asset standard typically result intangible asset recognise acquisition previously consequently goodwill arise new standard affect group effective tax rate currently tax benefit record respect goodwill amortisation base group result group effective tax rate expect reduce percentage point ia revise intangible assetsamongst matter revise standard typically result intangible asset recognise inlicense arrangement similar research development alliance previously expenditure record research development expense revise standard require prospective application ia revise presentation financial statement matter revise standard require minority interest include group equity separate category balance sheet increase group equity million swiss franc effective january group expect new revise standard significant effect group result financial position group draw attention fact fully apply exist iason financial instrument financial risk management group expose financial risk arise group underlie operation corporate finance activity financial risk group expose predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie group subsidiarie genentech chugai treasury operation operational independence whilst work financial risk management framework consistent rest group information financial risk available annual report chugai genentech financial risk management group govern policy guideline approve senior management policy guideline cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policy guideline cover area cash management investment excess fund raise short longterm debt compliance policy guideline oversee segregate function group objective financial risk management contain deem appropriate exposure type financial risk mention order limit negative impact group financial income balance sheet group actively measure monitor manage financial risk exposure function pursuant segregation duty principle annual report note roche group consolidate financial statement accordance financial risk policy group manage market risk exposure deem appropriate use financial instrument derivative group policy practice enter derivative transaction trade speculative purpose purpose unrelated underlying business foreign exchange risk group operate world expose movement foreign currency affect net income financial position express swiss franc group actively monitor currency exposure appropriate enter transaction aim preserve value asset commitment anticipate transaction group use forward contract foreign exchange option crosscurrency swap hedge certain commit anticipate foreign exchange flow financing transaction net investment transaction exposure arise local currency pay receive transaction denominate foreign currency vary change exchange rate group company income primarily local currency significant expenditure especially purchase good resale interest repayment loan foreign currency similarly transaction exposure arise net balance monetary asset hold foreign currency local level group company manage exposure necessary mean financial instrument option forward contract addition group treasury monitor total worldwide exposure help comprehensive datum receive monthly basis translation exposurearise consolidation foreign currency denominate financial statement group foreign subsidiary effect group consolidated equity show currency translation movement group partially hedge net investment foreign currency take foreign currency loan issue foreign currency denominate debt instrument major translation exposure monitor regular basis significant group cash outflow research development production administration denominate swiss franc small proportion group cash inflow swiss franc denominate result increase value swiss franc relative currency adverse impact consolidate net income similarly relative fall value swiss franc favourable effect result publish swiss franc interest rate risk interest rate risk arise movement interest rate effect group net income financial position change interest rate cause variation interest income expense interest bear asset liability addition affect market value certain financial asset liability instrument describe follow section market risk interest rate group major debt instrument fix describe note group use interest rate derivative manage interest raterisk market risk financial asset change market value certain financial asset derivative instrument affect net income financial position group financial longterm asset hold strategic purpose marketable security hold fund management purpose risk loss value manage review prior invest continuous monitoring performance investment change risk profile investment equity bond debenture fix income instrument enter basis guideline regard liquidity credit rating annual report note roche group consolidate financial statement credit risk credit risk arise possibility counterparty transaction unable unwilling meet obligation cause financial loss group trade receivables subject policy active risk management focusse assessment country risk credit availability ongoing credit evaluation account monitor procedure significant concentration trade receivables counterparty credit risk group large number customer wide geographical spread credit exposure critical country group enter respective credit insurance country risk limit exposure continuously monitor exposure financial asset credit risk control set policy limit credit exposure highquality counterpartie regular review credit rating set define limit individual counterparty appropriate reduce exposure netting agreement isda international swap derivative association master agreement sign respective counterpartie maximum exposure credit risk result financial activity consider net agreement equal carrying financial asset credit exposure diversify different counterpartie liquidity risk group company need sufficient availability cash meet obligation individual company responsible cash management include shortterm investment cash surplus raise loan cover cash deficit subject guidance group certain case approval group level group maintain sufficient reserve cash readily realisable marketable security meet liquidity requirement times addition strong international creditworthiness group allow tomake efficient use international capital market financing purpose change group organisation list major group subsidiary associate company include note gain loss change group organisationin millions chf consumer health otc business gain loss disposal consumer health otc business gain loss disposal attributable roche prescription business vitamin fine chemical business impairment net asset gain loss disposal total disposal consumer health otc business discuss note disposal vitamin fine chemical business discuss note igen february group acquire control interest igen international inc igen public company headquartered gaithersburg maryland usa acquisition give group broad access human invitro diagnostic immunochemistry sector use electrochemiluminiscence ecl technology development elecsys product line acquisition approve extraordinary general meeting igen shareholders february clear relevant antitrust authority thetotal cash consideration pay million swiss franc incidental cost million swiss franc addition accumulate loss million swiss franc record equity hedge thistransaction remove equity include acquisition cost allocation total purchase consideration million swiss franc follow annual report note roche group consolidate financial statement igen acquisition net asset acquiredin million chf goodwill intangible asset defer income taxis cash net asset liability total goodwill acquire intangible asset amortise straightline basis year begin march igen acquisition impact operate profitin millions chf royalty expense preacquisition amortisation intangible asset effect operate profit exceptional item goodwill amortisation effect operating profit disetronic effective group acquire control interest disetronic public company headquarter burgdorf switzerland disetronic world leader research development commercialisation insulin pump injection system treatment diabete disetronic infusion system division roche diagnostic diabete care business area acquisition process disetronic injection system simultaneously resold disetronic founder chairman continue operate independent company group interest disetronic acquisition approve extraordinary general meeting disetronic shareholder april subsequently clear relevant antitrust authority group pay shareholders disetronic swiss franc cash roche nonvoting equity securities disetronic share net consideration pay million swiss franc million swiss franc cash million swiss franc form roche nonvoting equity security addition incidental cost million swiss franc cash flow change group organisationin millions chf acquisition igen disetronic acquisition total cash flow acquisition subsidiary associate company divestment consumer health otc business vitamin fine chemical business divestment total cash flow divestment subsidiary associate company amount net cash balance acquireddiveste companybusiness include cash outflow incidental transaction cost annual report note roche group consolidate financial statement segment information information business segment millions chf roche genentech chugai total prescription prescription prescription pharmaceutical segment revenue segment revenue divisional sale interdivisional sale divisional sale party operate profit exceptional item amortisation goodwill major legal case change group organisation segment result operate profit segment asset liabilitie divisional asset segment asset segment asset nonsegment asset total asset divisional liability segment liability segment liability nonsegment liability total liability segment information capital expenditure depreciation amortisation intangible asset impairment longterm asset restructuring expense research development cost income associate company investment associate company number employee chugai prescription result include million swiss franc writeoff fair value adjustment inventory arise acquisition accounting chugai note fair value adjustment write line inventory turnover fully write end quarter consumer health otc show discontinue business note segment result exclude total million swiss franc million swiss franc administration cost previously allocate consumer health otc business group publish segment result item transfer sale business reclassify business segment group continue business result annual report note roche group consolidate financial statement continue consumer health vitamin diagnostic business otc fine chemical group vitamin fine chemical show discontinue business note business sell effective september result include impairment charge million swiss franc net asset vitamin fine chemical business include cost corporate headquarter nonallocate administration cost refer group reassess view reduce restructure annual report note roche group consolidate financial statement information geographical segmentin millions chf sale party destination segment asset capital expenditure switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment asset consolidate total switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment asset consolidate total genentech effective september group acquire majority interest approximately genentech inc biotechnology company united states june group exercise option acquire remain share genentech june point genentech own subsidiary group july october march group complete public offering genentech common stock result group majority interest genentech issue additional share common stock connection equity compensation plan issue additional share purpose affiliation agreement group genentech provide thing genentech establish stock repurchase programme maintain group percentage ownership interest genentech annual report note roche group consolidate financial statement group ownership genentech decrease conversion redemption lyon dollar exchangeable note describe note change group ownership arise stock repurchase genentech exercise stock option genentech employee effective april genentech implement twoforone share split genentech common stock form stock dividend impact group percentage ownership genentech group consolidated result december group interest genentech genentech prescription show separate business segment segment information common stock genentech publicly trade list new york stock exchange symbol dna genentech prepare financial statement conformity accounting principle generally accept united states gaap file quarterly basis securities exchange commission sec difference ifrs gaap certain consolidation entry difference requirement international financial reporting standard ifrs gaap difference genentech standalone result gaap basis result genentech consolidate roche group accordance ifrs reconciliation genentech result usd chf usd chf million million million million operate margin gaap basis redemption cost special litigation item operate margin nonus gaap basis add deduct difference consolidation entry add redemption cost difference consolidation entry operating profit exceptional item ifrs basis add deduct exceptional item amortisation goodwill major legal case segment resultoperate profit ifrs basis add deduct nonoperate item ifrs basis financial income income taxis net income ifrs basis minority interest percentage average year income applicable minority interest ifrs basis translate usd chf usd chf annual report note roche group consolidate financial statement follow acquisition group interest genentech june analysis carry acquisition accounting identify amount attributable inprocess research development iprd genentech gaap financial statement item record adjustment equity onetime expense ifrs item classify separate asset date acquisition form goodwill year subsequent goodwill amortisation expense respect iprd group result ifrs genentech adopt accounting standard fas fas effective january goodwill long amortise subject impairment test annually ifrs goodwill continues amortise subject testing impairment effective january group implement ifrs business combination date goodwill long amortise difference ifrs gaap relatively minor impact genentech stock repurchase stock option september genentechs board director authorise extension current stock repurchase programme repurchase million dollar genentechs common stock december previously december genentech board director authorise stock repurchase programme repurchase million dollar genentech common stock genentech repurchase common stock worth million dollar million swiss franc million dollar million swiss franc genentech employee stock purchase programme allow employee purchase genentech common stock low market value grant date purchase date thousand share genentech common stock purchase result cash inflow million swiss franc genentech stock option plan adopt amend april genentech shareholder approve equity incentive plan plan allow grant stock option incentive stock option stock purchase right share employee director consultant genentech incentive stock option stock purchase right grant plan date detail stock option show table restate effect twoforone share split genentech stock option number option thousand outstanding january grant exercised cancellation outstanding end year exercisable term option outstanding december option outstanding option exercisable weighted weight number weight average average number average outstanding year remain exercise exercisable exercise range exercise price usd thousand contractual life price usd thousand price usd total annual report note roche group consolidate financial statement genentech grant thousand option average exercise price usd option vest fouryear period expire fair value option grant estimate binomial model million swiss franc option exercise average exercise price ofusd cash inflow equivalent million swiss franc net accounting effect genentech stock repurchase stock option record minority interest seenote effective january group implement ifrs sharebase payment matter new standard require value equitysettle plan genentech stock option plan employee stock purchase programme estimate grant date record employee remuneration expense vest period example fair value million swiss franc option grant record expense subsequent fouryear vest period base initial work carry apply transitional restriction group estimate pretax expense genentechs equity compensation plan approximately million swiss franc impact transitional arrangement indicative future expense plan note matter discuss note group record income million swiss franc respect certain litigation matter genentech chugai effective october roche group chugai complete alliance create lead researchdriven japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai fully consolidated subsidiary group december group interest chugai chugai prescription show separate business segment segment information result chugais otc business include consumer health otc business segment segment information give note common stock chugai publicly trade list tokyo stock exchange chugai prepare financial statement conformity accounting principle generally accept japan jgaap file quarterly basis tokyo stock exchange difference ifrs jgaap certain consolidation entry difference requirement international financial reporting standard ifrs jgaap difference chugais standalone result jgaap basis result chugai consolidated roche group accordance ifrs acquire roche chugai treat acquisition ifrs jgaap alliance treat merger chugai nippon roche jgaap result chugai include goodwill fair value adjustment record roche result quantify table acquisition accounting include roche fair value adjustment impact net income need add minority interest calculation roche ifrs result roche ifrs result depreciation property plant equipment calculate straightline method chugais jgaap result reduce balance method additionally certain income expense notably restructure cost require jgaap report extraordinary item chugais jgaap result extraordinary item report operate profit line roche ifrs result item normally include operating profit treat extraordinary exceptional item restructure cost million swiss franc million swiss franc difference ifrs jgaap relatively minor impact annual report note roche group consolidate financial statement reconciliation chugai prescription resultsin millions chf chugai prescription operating profit exceptional item acquisition accounting impact ifrs basis writeoff fair value adjustment inventory depreciation property plant equipment amortisation acquisitionrelate intangible asset chugai prescription operating profit exceptional item ifrs basis add deduct exceptional item amortisation goodwill chugai prescription segment resultoperate profit ifrs basis add deduct chugai otcand nonoperate item ifrs basis financial income chugai otc income taxis net income ifrs basis minority interest calculation add acquisition accounting impact net income net income exclude acquisition accounting minority interest percentage average year income applicable minority interest ifrs basis translate jpy chf jpy chf dividend dividend distribute thirdpartie hold chugai share total million japanese yen million swiss franc million japanese yen million swiss franc record minority interest note dividend pay chugai roche eliminate consolidation intercompany item chugai otc july chugai announce sale otc business lion corporation sale complete effective december pretax gain disposal million swiss franc record early retirement programme chugai announce early retirement programme retirement date september end application period august total employee apply programme restructuring cost billion japanese yen million swiss franc record programme share repurchase chugai repurchase common share total consideration billion japanese yen million swiss franc result group ownership chugai increase net accounting effect chugai share repurchase record minority interest note annual report note roche group consolidate financial statement chugai convertible bond detail series chugai pharmaceutical unsecured convertible bond include conversion year give note stock acquisition right chugai adopt stock acquisition right programme programme allow grant right employee director chugai right entitle holder purchase chugai share aspecifie exercise price chugai stock acquisition right number right outstanding january grant exercised cancellation outstanding end year exercisable term right outstanding december right outstanding right exercisable number remain exercise number exercise year grant outstanding contractual life price jpy exercisable price jpy year year chugai grant right exercise price jpy right vest immediately expire fair value right grant estimate binomial model million swiss franc effective january group implement ifrs sharebase payment matter new standard require value equitysettle plan chugai stock acquisition right estimate grant date record expense vest period note consumer health otc business july group announce sale roche consumer health global otc overthecounter medicine business bayer group sale include production facility belong roche prescription business agreement bayer majority local business transfer bayer end small market transaction close completion expect half december divestment bayer complete measure term roche consumer health sale party july chugai announce sale otc business lion corporation sale complete effective december annual report note roche group consolidated financial statement gain disposal consumer health otc business roche prescription production facility december millions chf consideration net debt adjustment purchase price adjustment mechanism net proceed cash receivable bayer collect january incidental transaction cost net asset consumer health otc business production facility property plant equipment goodwill intangible asset inventory account receivable cash provision account payable net asset liability accumulate currency translation adjustment impairment restructuring charge accrual residual obligation retain roche group gain disposal discontinue business consumer health otc business segment continue business roche prescription business segment table include preliminary assessment net debt adjustment purchase price mechanism initial calculation impairment restructuring charge accrual residual obligation retain roche group final assessment calculation preliminary assessment disposal result tax expense currently estimate million swiss franc aftertax gain million swiss franc million swiss franc attributable minority interest give net income million swiss franc disposal cash inflow disposal net cash balance million swiss franc hold company consumer health otc business cash payment transaction cost million swiss franc million swiss franc term agreement majority cash proceed total million swiss franc transfer group january show receivable december balance sheet discontinuing business consumer health otc business segment consumer health otc business show discontinuing operation consolidate result represent separate major line business distinguish operationally financial reporting purpose result consumer health otc business segment show note annual report note roche group consolidate financial statement consumer health otc business amount include income statementin million chf sale party expense operate profit exceptional item amortisation goodwill major legal case change group organisation operate profit result associate company financial income profit taxis income taxis profit taxis minority interest net income figure exclude total million swiss franc million swiss franc administration overhead previously allocate consumer health otc business group publish segment result item transfer sale business reclassify business segment group continue business result group reassessing view reduce restructure consumer health otc business amount include balance sheetin millions chf december december property plant equipment longterm asset current asset total asset longterm debt provision current liability total liability net asset significant operating cash flow consumer health otc business million swiss franc million swiss franc arise operating profit exceptional item depreciation amortisation impairment significant investing finance cash flow consumer health otc business continue business roche prescription business segment production facility include sale bayer show roche prescription result date disposal production facility transfer bayer end include december balance sheet connection divestment roche consumer health roche prescription business reassess utilisation manufacturing facility infrastructure service capacity addition term agreement bayer roche prescription business agree certain interim manufacturing service obligation bayer result roche prescription business record impairment charge base estimate net selling price show table annual report note roche group consolidate financial statement bayer transaction impact roche prescription business segment millions chf net proceed incidental transaction cost net asset production facility impairment charge restructure charge accrual residual obligation retain roche prescription business gain loss disposal roche prescription business segment july separate transaction roche prescription business announce grant glaxosmithkline consumer healthcare exclusive license nonprescription right antiobesity drug orlistat market roche prescription medicine brand xenical agreement provide upfront payment million dollar million swiss franc additional payment achievement agree milestone royalty upfront payment receive initially report deferred income recognise income earn period development collaboration group retain right market xenical prescription drug right prescription nonprescription outside vitamin fine chemical business effective september receive final regulatory approval group complete sale global vitamin fine chemical business vfc business dutch company dsm impairment charge million swiss franc record june base assessment respective date difference expect net proceed disposal net asset vfc business take account residual obligation retain roche group preliminary assessment show additional loss disposal million swiss franc arise disposal vfc business final assessment expected finalise follow review approval group dsm implementation purchase price adjustment mechanism base current status review approval process adjustment preliminary estimate loss disposal gain loss disposal vitamin fine chemical businessin millions chf consideration net debt adjustment purchase price adjustment mechanism net proceed dsm receive cash dsm share incidental transaction cost net asset vfc business net impairment charge accrual residual obligation retain roche group gain loss disposal preliminary assessment disposal result tax benefit million swiss franc cash inflow disposal net cash balance million swiss franc hold company vfc business million swiss franc follow sale vfc business certain asset liability vitamin fine chemical division mainly associate vitamin case remain group describe section vitamin case addition group give dsm certain indemnity respect remedial action annual report note roche group consolidate financial statement site vfc business require environmental law arrangement place utilisation certain asset certain purchasing contract adopt dsm preferred supplier pharmaceutical ingredient arrangement group guarantee purchase period year begin january product sale value total million euro group reimburse dsm unutilised amount arrangement consist certain residual obligation fully accrue vitamin fine chemical division show discontinuing operation consolidate result result vfc business sell dsm include consolidated result group sale september result vitamin fine chemical business segment show note vfc business amount include income statementin millions chf vitamin case vitamin fine vfc business residual chemical sell dsm amount business sale party expense operate profit exceptional item amortisation goodwill major legal case change group organisation operate profit result associate company financial income profit taxis income taxis profit taxis minority interest net income remain segment liabilitie vfc business show note consist primarily provision relate vitamin case matter transfer dsm addition vitamin case payment cash flow vfc business month prior sale dsm consist operate cash flow million swiss franc finance cash outflow million swiss franc invest cash outflow million swiss franc vitamin case follow settlement agreement department justice pricing practice vitamin market overall settlement agreement class action suit bring buyer bulk vitamin group record provision respect vitamin case provision group well estimate time total liability arise take account currency movement time value money provision legal fee record separately december december base development litigation recent settlement negotiation group record additional provision million swiss franc respectively january district columbia circuit court appeal rule nonus plaintiff bring claim court antitrust law allege damage suffer transaction outside united states connection vitamin case june supreme court united states nullify decision district columbia circuit court appeal class action litigation bring behalf nonus purchaser bulk vitamin roche manufacturer addition nullification annual report note roche group consolidate financial statement decision low court supreme court remand case low court review alternative argument permit claim proceed district columbia circuit court appeal ask party submit write brief oral hearing schedule april provision record respect litigation eventual outcome uncertain stage total payment year million swiss franc million swiss franc charge provision previously record payment include million dollar million swiss franc direct customer united states group seek resolve remain outstanding issue time final amount involve uncertain remain provision record total million swiss franc base current litigation recent settlement agreement provision consider shortterm cash outflow expect arise discount time value money consider material case litigation negotiation progress possible ultimate liability different provision currently record disposal process liability respect vitamin case discuss remain roche group roche dsm sign indemnity cooperation agreement roche provide dsm certain indemnity guarantee connection vitamin case major legal case income expense major legal casesin millions chf igen litigation writeoff intangible asset release provision genentech legal case receipt payment settlement total income expense igen litigation february united states district court maryland enter judgement civil litigation roche diagnostic gmbh germany rdg igen international inc igen claim relate licensing igen electrochemiluminescence ecl technology rdg court conclude breach licence agreement material igen right terminate licence agreement award igen million dollar compensatory damage million dollar punitive damage july united states court appeals fourth circuit reverse substantial damage award rdg court reverse find rdg engage unfair competition continuation patent lawsuit igen rdgs affiliate company set aside claim court eliminate basis award million dollar punitive damage rdg court hold rdg violate imply covenant good faith fair deal license agreement set aside award million dollar compensatory damage claim total court eliminate million dollar million dollar judgement enter rdg court leave intact jurys award remain damage find igen terminate license agreement rdg igen notify rdg igen terminate license agreement july group igen announce plan group acquire igen acquisition complete effective february note previous license agreement terminate group write intangible asset technology record time acquisition corange group roche group net book value million swiss franc time group release income million swiss franc litigation provision balance provision remain outstanding compensatory damage award net amount expense totalling million swiss franc record expense major legal case result annual report note roche group consolidate financial statement march rdg pay million dollar collateral deposit account relation igen litigation follow entry final judgement rdg pay remain million dollar million swiss franc respect remain compensatory damage igen collateral deposit account repay group net cash inflow transaction million swiss franc genentech legal case group record income million swiss franc respect certain litigation settlement include litigation involve amgen june genentech announce los angeles county superior court jury vote award city hope medical center approximately million dollar compensatory damage base find breach agreement genentech city hope june jury vote award city hope million dollar punitive damage case september genentech file notice appeal jury verdict damage awards california court appeal october court appeal affirm verdict damage award respect october genentech announce seek review california supreme court discretion case review november genentech file petition review california supreme court city hope file answer december genentech file reply december california supreme court rule petition provision classify shortterm record damage award appeal process interest accrue total damage simple annual rate follow judgement interest million swiss franc million swiss franc record time cost provision interest expense note october genentech enter arrangement party insurance company post surety bond million dollar connection judgement arrangement genentech pledge million dollar cash investment secure bond increase million dollar million dollar million swiss franc report restrict cash current asset note addition genentech party patent infringement suit file chiron corporation june district court eastern district california sacramento respect herceptin june court issue decision summary judgement motion file jury trial suit begin august follow phase trial base finding jury court enter judgement favour genentech november chiron file notice appeal court appeal federal circuit december genentech file notice crossappeal court april genentech announce court appeal federal circuit unanimously affirm judgement district court eastern district california sacramento find favour genentech chiron file petition rehear court appeal motion subsequently deny october chiron file petition united states supreme court seek review judgment favour genentech january supreme court announce deny review judgment august united states patent trademark office declare interference chiron patent involve lawsuit patent application exclusively license genentech university pennsylvania relate antiher antibody declare interference patent office determine substantial question inventor chiron patent invent technology involve entitle patent subsequently patent office redeclare interference include addition abovereference chiron patent university patent application number patent patent application own chiron genentech include chiron patent issue second patent infringement lawsuit file march genentech chiron november patent office issue ruling preliminary motion ruling terminate interference involve patent application reference genentech license university redeclare interference genentech chiron patent patent application determination affect validity genentech chiron patent patent application involve remain interference interference proceeding ongoing include possibility ruling preliminary motion challenge appeal outcome matter annual report note roche group consolidated financial statement determine time connection second patent infringement lawsuit file march genentech chiron discovery case currently stay january arbitration proceeding begin genentech tanox biosystems inc tanox july settlement crosslicensing agreement relate development manufacture certain antibody product direct immunoglobin include xolair tanox claim breach agreement genentech counterclaim february genentech announce agreement reach tanox genentech novartis settle litigation party finalise detailed term threeparty collaboration settlement genentech novartis reimburse tanox million dollar portion development cost august genentech amgen inc announce settlement patent litigation district court northern district california settlement agreement party agree dismiss claim counterclaim settlement amgen onetime payment genentech november genentech bayer settle breachofcontract action genentech bring bayer relate bayer manufacture sale factor viii license agreement bayer genentech settlement bayer onetime payment genentech income major legal case million swiss franc record result respect settlement october genentech receive subpoena united states department justice request document relate promotion rituxan prescription product approve treatment relapse refractory lowgrade follicular positive bcell nonhodgkin lymphoma genentech cooperating associate investigation genentech advise civil criminal nature potential outcome matter determined time genentech annual report quarterly sec filing contain detailed disclosure litigation matter require gaap include detail matter include information litigation currently significant matter refer employee benefit employee remunerationin millions chf wage salary social security cost postemployment benefit define benefit plan postemployment benefit define contribution plan employee benefit total employee remuneration charge employee benefit include relevant expenditure line function number employee yearend employee benefit consist mainly life insurance scheme certain insurance scheme provide medical cover long shortterm disability benefit pension postemployment benefit employee cover retirement benefit plan sponsor group company nature plan vary accord legal regulation fiscal requirement economic condition country employee employ major plan define benefit plan large locate switzerland united states germany united kingdom japan postemployment benefit consist postretirement healthcare life insurance scheme principally united states plan usually fund payment group employee trust independent group finance plan unfunded notably major define benefit plan germany liability obligation record group balance sheet annual report note roche group consolidate financial statement define benefit plan expense recognisedin millions chf current service cost interest cost expect return plan asset net actuarial gain loss recognise past service cost gain loss curtailment total include employee remuneration actual return plan asset million swiss franc million swiss franc december group pay additional contribution million swiss franc swiss post employment define benefit plan payment include contribution pay table account recognise surplus fund pension plan group consolidate financial statement include actuarial calculation group pension expense balance define benefit plan movement recognise net asset liabilityin millions chf beginning year disetronic consumer health otc business vitamin fine chemical business total expense include employee remuneration contribution pay benefit pay unfunded plan currency translation effect end year define benefit plan amount recognise balance sheetin millions chf fund plan actuarial present value fund obligation past present employee plan asset hold trust fair value plan asset excess deficit actuarial present value fund obligation unrecognise actuarial gain loss unrecognise past service cost net recognise asset liability fund obligation past present employee unfunded plan actuarial present value fund obligation past present employee unrecognise actuarial gain loss unrecognise past service cost recognise liability actuarial present value unfunded obligation past present employee total recognise asset liability fund unfunded obligation past present employee report surplus recognise longterm asset deficit recognise noncurrent liability total net asset liability recognise annual report note roche group consolidated financial statement amount include nonpension postemployment benefit scheme principally medical plan show postemployment benefit plansin millions chf actuarial present value obligation past present employee plan asset hold trust fair value plan asset excess deficit actuarial present value fund obligation unrecognised actuarial gain loss net recognise asset liability amount recognise balance sheet postemployment define benefit plan predominantly non current report longterm asset noncurrent liability plan asset fund plan include group equity instrument group operate define benefit scheme country actuarial assumption vary base local economic social condition range assumption actuarial valuation significant define benefit plan country stable currency interest rate show define benefit plan actuarial assumption weight weight average range average range discount rate project rate remuneration growth expect rate return plan asset healthcare cost trend rate employee stock option equity compensation benefit roche option plan group offer nonvoting equity security option certain director management exercise price market price nonvoting equity security date issue option non tradable sevenyear duration vest phase basis year group cover obligation purchase nonvoting equity security derivative thereon note cost instrument report equity instrument equity balance sheet option exercise cash receive credit equity instrument impact income statement employer social insurance cost administrative cost plan previous option compensation plan group purchase option directly thirdparty financial institution grant certain employee closed option grant detail roche option plan show table roche option plan number option outstanding january grant exercised cancellation outstanding end year exercisable annual report note roche group consolidate financial statement term option outstanding december option outstanding option exercisable weighted weighted weight average average average number year remain exercise number exercise year grant outstanding contractual life price chf exercisable price chf total group grant option average exercise price chf option vest threeyear period expire fair value option grant estimate binomial model million swiss franc option exercise average exercise price chf cash inflow equivalent million swiss franc effective january group implement ifrs sharebase payment matter new standard require value equitysettle plan roche option plan estimate grant date record expense vest period note roche performance share plan group offer future nonvoting equity security award board discretion cash equivalent certain director key senior manager programme establish beginning effect year nonvoting equity security grant depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant discretion board director plan conclude end non vote equity security vest fair value million swiss franc allocate recipient blackout period end cost plan accrue vest period grant base final fair value award estimate balance sheet date year cost plan million swiss franc million swiss franc report relevant operating expense category board approve new threeyear cycle roche performance share plan operate roche connect programme enable employee worldwide united states certain country regular deduction salary purchase nonvoting equity security administer independent party group make contribution programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market nonvoting equity security hold december programme operational october year cost plan million swiss franc million swiss franc report relevant operating expense category stock appreciation right employee certain north american subsidiary group receive stock appreciation right sar compensation sar exercise vest period year cash payment base market price group american depositary receipt adr point exercise exceed strike price grant price issuance annual report note roche group consolidate financial statement stock appreciation right number right outstanding january grant exercised cancellation outstanding end year exercisable amount record consolidated financial statement expense million chf accrual million chf term right outstanding december right outstanding right exercisable weighted weight average average number exercise number exercise year grant outstanding expiry price usd exercisable price usd award award award award total group grant right average exercise price usd right vest threeyear period expire fair value right grant estimate binomial model million swiss franc right exercise average exercise price usd cash outflow equivalent million swiss franc follow approval roche global longterm incentive programme group future plan award cashsettle sar base market price adr roche global longterm incentive programme board approve new global longterm incentive programme onwards available certain director management employee select discretion group programme consist stocksettle stock appreciation right ssar group alternative grant award exist roche option plan ssar employee right receive nonvoting equity security reflect value appreciation market price nonvoting equity security grant date exercise date group cover obligation purchase nonvoting equity security derivative thereon genentech chugai plan genentech stock option plan discuss note chugai stock acquisition right programme discuss note annual report note roche group consolidate financial statement operating income operate incomein millions chf royalty income gain disposal product total operating income continuous realignment product portfolio group periodically dispose product line long consider core product priority product development portfolio proceed reinveste group inlicense arrangement research development alliance collaboration february group announce sale exclusive rights soriatane connetic corporation cash receive million swiss franc august group agree license sell certain patent right patent portfolio party cash receive million swiss franc september group announce sale protein design labs pdl business relate zenapax product worldwide disease indication organ transplantation group continue market zenapax transplantation indication point pdl option purchase cash receive million swiss franc group pdl sign separate agreement develop commercialise zenapax asthma relate respiratory disease disposal product concern book value gain disposal cash proceed disposal report operate profit roche prescription segment operating expense operate expensesin millions chf royalty expense restructuring expense impairment property plant equipment impairment intangible asset stock appreciation right total operating expense annual report note roche group consolidate financial statement financial income financial incomein millions chf gain sale equity security loss sale equity security dividend income gain loss equity derivative net writedown impairment equity security net income equity security interest income gain sale debt security loss sale debt security writedown impairment longterm loan net interest income income debt security interest expense amortisation discount debt instrument gain loss interest rate derivative net time cost provision net interest expense foreign exchange gain loss net gain loss foreign currency derivative net net foreign exchange gain loss net financial income expense total net financial income exceptional income bond conversion redemption group converted redeem certain debt instrument debt reduce million swiss franc total cash outflow million swiss franc net pretax gain million swiss franc result show net gain report exceptional item materiality gain order fairly present group result detail give note impact bond conversion redemptionin millions chf exceptional income bond conversion increase redemption reduction pretax debt cash outflow lyon dollar exchangeable note lyon iii dollar exchangeable note chameleon dollar bond lyon dollar exchangeable note limited conversion prefer stock total annual report note roche group consolidate financial statement income taxis income tax expensesin millions chf current income taxis adjustment recognise current tax prior period defer income taxis total charge income taxis group operate world subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate group average expect tax rate increase significance genentech chugai cause increase rate offset ongoing improvement group structure group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax ratein million chf group average expect tax rate tax effect unrecognised tax loss nontaxable incomenondeductible expense impairment financial asset difference continue business exceptional item effective tax rate profit income tax profit income tax tax taxis rate tax taxis rate continue business exceptional item effective tax rate amortisation goodwill major legal case change group organisation continue business exceptional income bond conversion redemption continue business effective tax rate discontinuing business change group organisation discontinuing business group effective tax rate annual report note roche group consolidated financial statement income tax asset liabilitiesin millions chf current income taxis current income tax asset current income tax liability net current income tax asset liability defer income taxis defer income tax asset defer income tax liability net defer income tax asset liability defer income tax asset recognise tax loss carry forwards extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance million swiss franc million swiss franc million swiss franc expire year million swiss franc expire year remain million swiss franc loss expire year defer income tax liability establish withholding tax taxis payable unremitted earning certain foreign subsidiary amount currently regard permanently reinveste unremitted earning total billion swiss franc december billion swiss franc defer income tax asset liability defer income tax charge credit attributable follow item defer income taxis movement recognise net asset liabilitiesin millions chf property plant equipment restructure temporary intangible asset provision difference total net defer income tax asset liability begin year charge credit income statement charge credit equity acquisition igen disposal consumer health otc business currency translation effect net defer income tax asset liability end year net defer income tax asset liability begin year charge credit income statement charge credit equity disetronic disposal vitamin fine chemical business currency translation effect net defer income tax asset liability end year annual report note roche group consolidate financial statement property plant equipment property plant equipment movement carry value assetsin million chf building land machinery construction improve land ment equipment progress total total net book value beginning year disetronic disposal consumer health otc business disposal vitamin fine chemical business addition disposal transfer depreciation charge impairment charge currency translation effect end year december cost accumulate depreciation net book value decrease property plant equipment million swiss franc disposal otc business consist asset transfer business million swiss franc impairment charge million swiss franc note finance lease december capitalise cost property plant equipment finance lease amount million swiss franc million swiss franc net book value asset amount million swiss franc million swiss franc finance lease present value future minimum lease paymentsin millions chf year year year total present value minimum lease payment group company party number finance lease significant enter genentech respect manufacturing facility vacaville california certain building south sanfrancisco site lease expiry genentech purchase property predetermine sell property party renew lease property sell party low finance lessor genentech agree residual value guarantee pay lessor agree percentage finance lessor genentech require maintain financial covenant form certain predefine financial ratio limited debt assume carry value lease obligation million dollar million swiss franc annual report note roche group consolidate financial statement genentech leasesin millions usd approximate maximum initial fair value residual property lease expiry value guarantee vacaville november south san francisco june total operating lease total operating lease rental expense million swiss franc million swiss franc operating lease future minimum payment noncancellable lease million chf year year year total minimum payment group company party number operating lease mainly plant machinery include motor vehicle certain shortterm property rental arrangement impose significant restriction group capital commitment group capital commitment purchase construction property plant equipment total billion swiss franc billion swiss franc addition december genentech enter master lease agreement lease property south san francisco genentechs aggregate lease payment estimate approximately million dollar goodwill goodwill movement carry value assetsin millions chf net book value beginning year igen acquisition disetronic acquisition disposal consumer health otc business amortisation charge impairment charge currency translation effect end year december cost accumulate amortisation net book value genentech acquisition corange acquisition chugai acquisition disetronic acquisition igen acquisition total annual report note roche group consolidated financial statement goodwill arise investment associate company classify investment associate company note effective january group implement ifrs business combination matter new standard require amortisation goodwill cease date implementation goodwill continue test impairment standard require prospective application standard apply goodwill amortisation expense million swiss franc record additional impairment necessary intangible asset intangible asset movement carry value assetsin million chf patent licence trademark intangible asset acquisition relate total total net book value beginning year igen acquisition disetronic acquisition disposal consumer health otc business addition disposal amortisation charge impairment charge igen litigation currency translation effect end year december cost accumulate amortisation net book value remain useful life genentech acquisition year corange acquisition year chugai acquisition year disetronic acquisition year igen acquisition year kytril year total majority group intangible asset result acquisition group patent license trademark intangible asset record fair value acquisition accounting subsequently amortise useful life kytril intangible asset arise purchase group global rights kytril granisetron smithkline beecham december group currently internally generate intangible asset development criterion recognition asset meet associate company group investment associate company account equity method goodwillarise investment associate company classify investment associate company annual report note roche group consolidate financial statement investment associated companiesin millions chf share net income balance sheet value basilea pharmaceutica switzerland investment associate company total investment associate company basilea pharmaceutica group owns noncontrolle interest basilea pharmaceutica ltd basilea basilea swiss biotechnology company antibacterial antifungal dermatology field group major investment associate tripath inc antisoma additional information company give note transaction group associate company give note april group announce long continue joint development renal transplantation drug isatx isotechnika result group long potential exercise significant influence isotechnika accordingly isotechnika long report associate company impairment loss million swiss franc record group investment associate joint venture group interest joint venture report financial statement proportionate consolidation method significant joint venture detailed bayer joint venturea disposal roche consumer health business note group sell bayer stake bayer roche llc joint venture bayer overthecounter otc field market distribute product aleve certain otc product united states joint venture recognise income statement balance sheet amount millions chf income statement sale expense net income taxis balance sheet longterm asset current asset noncurrent liabilitie current liability net asset financial longterm asset financial longterm assetsin millions chf availableforsale investment heldtomaturity investment loan receivable longterm trade receivable restrict cash total financial longterm asset prepay employee benefit total longterm asset annual report note roche group consolidate financial statement financial longterm asset hold strategic purpose classified noncurrent availableforsale investment mainly equity investment effective interest rate heldtomaturity investment loan receivable comprise loan party term year restrict cash include million dollar million swiss franc cash investment pledge genentech connection city hope litigation note include current asset note inventory inventory million chf raw material supply work process finish good intermediate provision slowmove obsolete inventory total inventory inventory hold net realisable value carry value million swiss franc million swiss franc result disposal consumer health otc business inventory decrease million swiss franc effective december note result disposal vitamin fine chemical business inventory decrease million swiss franc effective september note account receivable account receivablein millions chf trade account receivable note receivable provision doubtful account total account receivable december account receivable include amount denominate dollar equivalent billion swiss franc billion swiss franc amount denominate euro equivalent billion swiss franc billion swiss franc bad debt expense million swiss franc million swiss franc current asset current assetsin millions chf accrue interest income prepaid expense derivative financial instrument restrict cash receivables total current asset restrict cash consist million dollar million swiss franc cash investment pledge genentech connection city hope litigation note include financial longterm asset note annual report note roche group consolidate financial statement marketable security marketable securitiesin millions chf heldfortrade investment bond debenture availableforsale current investment share bond debenture money market instrument time account month total marketable security marketable security hold fund management purpose classify current primarily denominate swiss franc euros dollar pound sterling investment hold strategic purpose classify noncurrent note share consist primarily readily saleable equity security bond debenturesin million chf average effective contract maturity interest rate year year year total bond debenture year year year total bond debenture money market instrument generally fix interest rate range depend currency denominate contract mature year december cash cash equivalent cash cash equivalentsin millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent annual report note roche group consolidated financial statement account payable account payablein millions chf trade account payable taxis payable account payable total account payable accrue current liability accrue current liabilitiesin millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue liability total accrue current liability provision contingent liability provision movement recognise liability millions chf environmental legal restructuring provision provision provision total total beginning year disposal consumer health otc business vitamin case additional provision create utilise year major legal case additional provision create unused amount reverse utilise year provision additional provision create unused amount reverse utilise year increase discount passage time change discount rate currency translation effect end year current portion provision noncurrent portion provision total provision expect outflow resource year year year year total provision annual report note roche group consolidate financial statement environmental legal provision provision include million swiss franc million swiss franc environmental matter million swiss franc million swiss franc litigation include major legal case vitamin case provision environmental matter cover separate environmental issue number country approximately half preexist company acquire group nature amount time outflow difficult predict group estimate approximately half provide result cash outflow year significant provision discount legal provision consist mainly major legal case notably city hope medical center litigation note vitamin case note amount timing uncertainty outflow discuss note discount rate remain legal provision account balance consist number separate legal matter group company majority cash outflow expect occur year dependent development litigation significant provision discount major legal case describe note vitamin case describe note litigation matter currently significant describe carvedilol arbitrationroche diagnostic gmbh rdg smithkline beecham cork ltd party arbitration concern rdgs termination carvedilol license agreement amend relate licensing comarkete carvedilol rdg submit claim damage arbitration tribunal zurich submit counterclaim assert invalidity rdgs termination claim damage final decision arbitration tribunal expect early provision record rdg disclose seriously prejudice rdgs position matter applera litigation october applera corporation applera file suit group superior court california file notice arbitration american arbitration association superior court lawsuit arbitration demand claim concern interpretation enforcement contract group applera commercialisation polymerase chain reaction pcr technology claim seek termination certain contract declaration right obligation contract monetary damage relief unspecified allege breach agreement party december group file response arbitration proceeding day group respond appleras complaint superior court proceeding petitioning court compel arbitration claim allege applera stay lawsuit pende completion arbitration october court appeal state california rule petition compel arbitration grant remand case superior court direction grant petition meeting arbitration place february provision record respect matter outcome determined date financial statement promega litigationin group file suit promega corporation promega allege patent infringement breach licence agreement relate polymerase chain reaction pcr technology district court northern district california decide patent concern unenforceable reject breach licence claim suit allege infringement pcr patent progress november group notify promega file nonpublic qui tam action group district court eastern district west virginia march complaint file false claim act allege federal government overcharge purchase pcr enzyme product july federal government notify court decision intervene promegas complaint november court order complaint unseal group file motion dismiss complaint august court dismiss complaint prejudice annual report note roche group consolidate financial statement restructure provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group remain amount respect obligation employee arise pharmaceutical division restructure previous restructuring plan timing cash outflow reasonably certain global basis show table significant provision discount provision provision consist claim arise trade provision group company fit category timing cash outflow nature uncertain good estimate show table provision discount time value money consider material case contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group engage subject physical risk kind nature frequency development event cover insurance effect future operation earning predictable note respect vitamin case note respect major legal case group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group well estimate future commitment payment million swiss franc million swiss franc million swiss franc noncurrent liability noncurrent liabilitiesin millions chf defer income longterm liability total noncurrent liability debt debt recognise liabilitiesin millions chf debt instrument amount bank financial institution capitalise lease obligation borrowing total debt report longterm debt shortterm debt total debt annual report note roche group consolidate financial statement debt repayment termsin millions chf year year year year year year total debt lyon zero coupon dollar exchangeable note reflect year holder note request group purchase note fair value debt instrument billion swiss franc billion swiss franc fair value total debt billion swiss franc billion swiss franc calculate base present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period pledge group asset connection debt note obligation arising lease genentech secure property plant equipment net book value million swiss franc december amount bank financial institution interest rate amount primarily denominate euro average approximately repayment date vary year million swiss franc million swiss franc year debt instrument recognise liability effective interest rate debt instrumentsin million chf effective interest rate european medium term note programme bond october principal million euro bond august principal million pound sterling bond october principal million dollar swiss franc bond rodeo march principal billion swiss franc dollar bond chameleon july principal million dollar billion dollar zero coupon dollar exchangeable note lyon iii principal billion dollar lyon january principal billion dollar lyon july principal billion dollars annual report note roche group consolidate financial statement effective interest rate japanese yen exchangeable bond sumo march principal billion japanese yen limited conversion prefer stock november japanese yen convertible bond issue chugai series chugai pharmaceutical unsecured convertible bond september principal billion japanese yen billion japanese yen total debt instrument weight average effective interest rate unamortised discount include carry value debt instrument million chf swiss franc bond dollar bond euro bond sterle bond zero coupon dollar exchangeable note japanese yen exchangeable bond total unamortised discount issue new debt instrument issue new debt instrument group establish european medium term note programme issue subsequently cash inflow issue new debt instrument millions chf european medium term note programme eurodenominate bond issue april sterlingdenominated bond issue august dollardenominated bond issue october total cash inflow new issue year repayment redemption conversion debt instrument group converted redeem certain debt instrument debt reduce million swiss franc total cash outflow million swiss franc net pretax gain million swiss franc result show note net gain report exceptional item themateriality transaction describe conversion redemption lyon dollar exchangeable note march group exercise option note redemption april original issue plus accrue original issue discount oid effective interest rate note period april note principal million dollar call conversion holder remain note redeem cash april total genentech share meet obligation result group ownership genentech decrease group realise pretax gain million swiss franc disposal interest genentech redemption remain note annual report note roche group consolidate financial statement redemption lyon iii dollar exchangeable note april group exercise option note redemption original issue plus accrue original issue discount oid effective interest rate note note principal billion dollar redeem cash group realise pretax loss million swiss franc early redemption note partial redemption chameleon dollar bond june group announce tender offer redemption chameleon bond effective interest rate bond tender offer expire june pricing june point bond principal million dollar represent approximately outstanding bond tender redemption settlement june group realise pretax loss million swiss franc partial early redemption bond redemption limited conversion prefer stock mandatory redemption date november group redeem remain instrument original issue plus accrue interest effective interest rate instrument instrument principal million dollar redeem cash group realise gain loss redemption instrument reassessment probable redemption date lyon dollar exchangeable note effective september group reassess likely future cash outflow instrument conclude appropriate consider date july probable date cash flow accordingly effective interest rate method group record pretax expense million swiss franc increase debt reflect increase carry value debt allow accrete value meet issue price plus accrue original issue discount oid july cash effect partial conversion series chugai pharmaceutical unsecured convertible bond bond face value billion japanese yen million swiss franc convert share chugai group percentage ownership chugai unaffected conversion group bond convertible chugai share mirror chugai outstanding party net accounting effect chugai convertible bond conversion chugai share repurchase record minority interest note conversion helveticus swiss franc convertible bond date july remain swiss franc convertible bond originally issue convert nonvoting equity security genussscheinea total nonvoting equity security meet conversion obligation helveticus bond accordance term bond additional cash payment chf bond conversion remain principal conversion reduce debt million swiss franc million swiss franc form nonvoting equity security million swiss franc form cash cash outflow repayment redemption debt instrumentsin million chf lyon dollar exchangeable note lyon iii dollar exchangeable note chameleon dollar bond limit conversion prefer stock bullet swiss franc bond lyon dollar exchangeable note helveticus swiss franc convertible bond total cash outflow repayment redemption year term outstanding convertible debt instrument lyon note exchangeable nonvoting equity security nes american depositary share ad exchange ratio ness exchange adss usd principal maturity note group purchase note forcash option holder january annual report note roche group consolidate financial statement july july purchase price usd principal note usd usd usd respectively addition note redeemable option group time july issue price plus accrue original issue discount oid note outstanding december exchange require nonvoting equity security meet obligation sumo bond jpy par value exchangeable nonvoting equity security roche holding ltd bond redeemable maturity issue price plus accrue original issue discount oid bond outstanding december exchange require nonvoting equity security meet obligation series chugai pharmaceutical unsecured convertible bond bond jpy par value convertible share chugai conversion option bondholder time date september bond redeemable maturity issue price bond outstanding december convert require chugai share exactly meet obligation group percentage ownership chugai affect conversion group bond convertible chugai share mirror chugai outstanding party derivative financial instrument appropriate circumstance group use derivative financial instrument risk management trading strategy discuss note derivative financial instrument carry fair value method determine fair value describe note derivative financial instrumentsin millions chf asset liability foreign currency derivative forward exchange contract swap interest rate derivative swap derivative total derivative financial instrument hedge accounting group accounting policy hedge accounting describe note require qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement describe note group financial risk management policy cover foreign exchange risk interest rate risk market risk credit risk liquidity risk deem appropriate certain risk alter use derivative transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income group generally limit use hedge account certain significant transaction consequently december group fair value hedge cash flow hedge hedge net investment foreign entity meet strict requirement qualify hedge accounting apart describe annual report note roche group consolidated financial statement group hedge fix term debt instrument interest rate swap december instrument designate qualify fair value hedge record balance sheet fair value million swiss franc genentech nonus dollar cash flow future royalty income development expense expect year hedge transaction exposure genentech enter derivative financial instrument option forward contract genentech equity investment biotechnology company subject great risk market fluctuation stock market general manage exposure genentech enter derivative financial instrument zero cost collar forward contract december instrument designate qualify hedge accounting record balance sheet fair value million swiss franc matter describe genentech annual report quarterly sec filing movement fair value reserve designate cash flow hedge include note equity share capital december share capital roche holding ltd group parent company consist share nominal value swiss franc precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share describe note base information supply group novartis international ltd basel affiliates participation issue share nonvoting equity securitiesgenussscheine december nonvoting equity security issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate dividend april shareholder approve distribution dividend swiss franc share non vote equity security swiss franc respect business year distribution holder outstanding share nonvoting equity security total million swiss franc million swiss franc record retain earning board propose dividend business year swiss franc share nonvoting equity security subject approval annual general meeting february equity instrument follow redemption lyon exchangeable note april note light restructure group treasury operation debt financing group carry comprehensive review arrangement cover potential conversion obligation arise convertible debt instrument group refinance instrument cover potential obligation deliver nonvoting equity security group sell nonvoting equity security previously hold series transaction addition nonvoting equity security utilise disetronic transaction note utilise conversion helveticus bond note group agree counterpartie restructure previous arrangement writtenshort option purchasedlong option strike price combine effect forward purchase december arrangement close addition thegroup purchase counterpartie low exercise price option lepos group right purchase nonvoting equity security low strike price annual report note roche group consolidate financial statement equity instrumentsin equivalent number nonvoting equity security december december nonvoting equity security low exercise price option forward purchase derivative instrument total nonvoting equity instrument equity instrument record equity original cost acquisition detail equity instrument hold december show table fair value disclose information purpose equity instrument supplementary information equivalent number nonvoting strike price fair value equity security maturity chf million chf nonvoting equity security low exercise price option feb nov derivative instrument roche option plan feb feb options feb apr total nonvoting equity security low exercise price option mainly hold potential conversion obligation arise group convertible debt instrument note group potential obligation employee roche option plan note cover option exercisable time maturity group hold residual number option purchase use group previous option compensation scheme close note net cash inflow transaction equity instrument million swiss franc net cash outflow million swiss franc additionally net cash outflow million swiss franc refinance instrument cover convertible debt obligation group hold share earning share nonvoting equity security basic earning share nonvoting equity security calculation basic earning share nonvoting equity security number share non vote equity security reduce weight average number nonvoting equity security hold group period annual report note roche group consolidate financial statement basic earning share nonvoting equity security continue business group net income millions chf number share million number nonvoting equity security millions weight average number nonvoting equity security hold million weight average number share nonvoting equity security issue calculate basic earning share millions basic earning share nonvoting equity security chf dilute earning share nonvoting equity security calculation dilute earning share nonvoting equity security net income weight average number share nonvoting equity security outstanding adjust effect dilutive potential share nonvoting equity security potential dilutive effect arise convertible debt instrument employee stock option plan outstanding convertible debt instrument convert lead reduction interest expense increase number share net dilutive effect earning share exercise outstanding vested employee stock option dilutive effect exercise outstanding vested genentech employee stock option dilutive effect net income genentech positive diluted earning share nonvoting equity security show potential impact dilutive effect earning share figure dilute earning share nonvoting equity security continue business group net income millions chf elimination interest expense net tax convertible debt instrument dilutive millions chf increase minority share group net income net tax assume outstanding genentech stock option exercise millions chf net income calculate diluted earning share million chf weight average number share nonvoting equity security issue million adjustment assume conversion convertible debt instrument dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf annual report note roche group consolidate financial statement fair value reserve fair value reserve movement recognise amountsin million chf fair value fair value reserve reserve available qualifying equity currency forsale cash flow conversion translation investment hedge option reserve total total beginning year change fair value fair value gain loss recognise income statement fair value gain loss recognise balance sheet defer income taxis minority interest currency translation gain loss end year include movement currency translation reserve million swiss franc relate consumer health otc business include calculation gain disposal business note minority interest minority interest movement recognise amount million chf beginning year minority share group net income net tax net effect movement fair value charge credit equity conversion redemption lyon dollar exchangeable note net effect exercise genentech stock option genentech stock repurchase net effect partial conversion chugai convertible bond chugai share repurchase chugai dividend payment currency translation effect end year genentech chugai total minority interest relate party control shareholder share capital roche holding ltd group parent company consist bearer share base information supply shareholder group pool voting right comprise vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri mscatherine oeri beatrice oeri maja oeri group hold share precede year represents issue share figure include share pooled voting right hold outside group individual member group annual report note roche group consolidate financial statement andr hoffmann andreas oeri members board director roche holding ltd capacity receive annual remuneration thousand swiss franc addition hoffmann oeri receive thousand swiss franc thousand swiss franc respectively time expense relate membership board committee retirement annual general meeting april drfritz gerber member mention shareholder group member board director roche hold limited period april gerber receive remuneration thousand swiss franc pension thousand swiss franc transaction group individual member shareholder group subsidiary associate company list major group subsidiary associate company include note transaction parent company subsidiary subsidiary eliminate consolidation transaction group associate company millions chf income statement income sale good supply service expense purchase good supply service milestone upfront payment balance sheet trade account receivable trade account payable key management personnel member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee total payment nonexecutive director remuneration expense million swiss franc million swiss franc payment franz humer member executive committee include figure executive committee member executive committee receive total remuneration show table remuneration member executive committeein millions chf salary bonus total cash remuneration pay option award equivalent number nonvoting equity security pension social insurance contribution pay group roche performance share plan member executive committee award nonvoting equity security fair value million swiss franc respect group performance note supplementary information give group corporate governance disclosure page annual report note roche group consolidate financial statement cash flow statement cash flow operating activity cash flow operating activity derive group primary activity describe divisional review calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show cash flow statement operate cash flow include income taxis pay activity include example taxis pay gain conversion redemption bond cash generate operationsin millions chf net income add nonoperate income expense income associate company financial income exceptional income bond conversion redemption income taxis income applicable minority interest operate profit depreciation property plant equipment amortisation goodwill amortisation intangible asset impairment longterm asset change group organisation chugai transaction writeoff fair value adjustment inventory major legal case expense define benefit postemployment plan adjustment cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate company business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect change group organisation cash generate group investment interest dividend receivedin million chf interest receive dividend receive total cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity annual report note roche group consolidate financial statement interest dividend paidin million chf interest pay dividend pay total significant noncash transaction significant noncash investing financing transaction include conversion lyon note genentech share note significant noncash investing financing transaction include nonvoting equity security disetronic acquisition note dsm share acquire disposal vitamin fine chemical business note nonvoting equity security conversion helveticus bond note subsequent event significant event balance sheet date annual report note roche group consolidated financial statement subsidiary associate company list company share capital equity interest country company city mill switzerland roche holding ltd basel chf stock exchange zurich valor share valor genussscheine isin share isin genussscheine market capitalisation chf mill basilea pharmaceutica ltd basel chf stock exchange zurich nasdaq biotech valor isin market capitalisation chf mill usa genentech inc south san francisco usd stock exchange new york incorporate delaware isin market capitalisation usd mill tripath imaging inc burlington usd stock exchange nasdaq isin market capitalisation usd mill japan chugai pharmaceutical ltd tokyo jpy stock exchange tokyo isin market capitalisation jpy mill great britain antisoma plc london gbp stock exchange london isin market capitalisation gbp mill nonliste company share capital equity interest country company city mill argentina producto roche qumica industrial buenos aire ars australia roche diagnostic australia pty limited castle hill aud roche product pty limited dee aud syntex australia limited north sydney aud austria roche austria gmbh vienna eur roche diagnostic gmbh vienna eur bangladesh roche bangladesh ltd dhaka bdt belgium roche brussels eur roche diagnostic belgium brussels eur bermuda canadian pharmholding ltd hamilton gbp corange international ltd hamilton usd corange ltd hamilton usd roche capital management ltd hamilton usd roche capital transaction limited hamilton usd roche financial investments ltd hamilton usd roche financial services ltd hamilton usd roche healthcare limited hamilton usd roche interfinance ltd hamilton usd roche international finance bermuda ltd hamilton usd roche international ltd hamilton usd roche intertrade ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd brazil produto roche qumico farmacuticos saso paulo brl roche diagnostic brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd john usd annual report note roche group consolidated financial statement share capital equity interest country company city mill chile producto farmoqumicos roche ltda santiago chile clp china roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai limited shanghai usd roche hong kong limited hong kong hkd roche center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche bogot cop costa rica producto roche san jos usd roche servicios san jos usd czech republic roche sro prague czk denmark roche hvidovre dkk dominican producto roche dominicana santo domingo dop republic ecuador roche ecuador quito usd egypt roche egypt sae giza egp ropharm limited giza egp salvador productos roche salvador san salvador usd finland roche espoo eur france hoffmannla roche france sas neuillysurseine eur roche diagnostic meylan eur roche neuillysurseine eur germany disetronic medical system gmbh sulzbach eur galenus mannheim gmbh mannheim eur hestia health care gmbh mannheim eur hoffmannla roche aktiengesellschaft grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen dem roche diagnostic gmbh mannheim eur great britain roche diagnostic ltd lewes gbp roche hold limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp greece roche hellas athens eur guatemala producto roche guatemala guatemala gtq guernsey roche capital market international limited peter port chf roche financial market limited peter port chf roche international finance peter port chf corporation limited honduras producto roche honduras tegucigalpa hnl hungary roche hungary ltd budapest huf india roche diagnostic india pvt ltd mumbai inr roche scientific company india mumbai inr private limited indonesia roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur italy roche diagnostic spa milan eur roche spa milan eur japan roche diagnostic tokyo jpy luxembourg pharminvest luxembourg eur malaysia roche diagnostic malaysia sdn bhd kuala lumpur myr roche malaysia sdn bhd kuala lumpur myr annual report note roche group consolidated financial statement share capital equity interest country company city mill mexico grupo roche syntex mxico mexico city mxn lakeside mxico mexico city mxn productos roche mexico city mxn syntex mexico city mxn morocco roche casablanca mad netherlands roche diagnostic nederland almere eur roche finance europe woerden eur roche nederland woerden eur roche pharmholde woerden eur new zealand roche diagnostic new zealand pty ltd auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua managua nio norway roche norge oslo nok pakistan roche pakistan ltd karachi pkr panama producto roche interamericana panama city usd producto roche panam panama city pab roche capital corporation panama city usd syntex corporation panama city usd peru producto roche qumica farmacutica lima pen philippine roche philippines inc makati php poland roche diagnostic polska warsaw pln roche polska warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas diagnsticos sociedade lindaavelha eur unipessoal lda puerto rico syntex puerto rico inc humacao usd russia roche moscow ltd moscow rub singapore roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd slovakia roche slovensko sro bratislava skk south africa roche product proprietary limited johannesburg zar south korea roche diagnostics korea ltd seoul krw roche korea company ltd seoul krw spain andreu roche madrid eur roche diagnostic barcelona eur roche farma madrid eur syntex roche madrid eur sweden roche stockholm sek roche diagnostic scandinavia bromma sek switzerland disetronic handel burgdorf chf disetronic holding burgdorf chf disetronic licensing burgdorf chf disetronic medical systems burgdorf chf hoffmannla roche ltd basel chf imib insitute medical informatic basel chf biostatistics ltd pharmexbio ltd zug chf rabbitair ltd zurichkloten chf roche diagnostic schweiz ltd rotkreuz chf roche diagnostic international ltd steinhausen chf roche finance ltd basel chf roche instrument center ltd rotkreuz chf roche kapitalmarkt basel chf roche pharma switzerland ltd reinach chf syntex corporation basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd annual report note roche group consolidated financial statement share capital equity interest country company city mill thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try uruguay roche international ltd montevideo uyu sapac corporation ltd montevideo uyu usa american roche international inc little fall cad disetronic medical systems inc paul usd hoffmannla roche inc nutley usd igen international inc wilmington usd roche carolina inc florence usd roche colorado corporation boulder usd roche diagnostic corporation indianapoli usd roche holdings inc wilmington usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche palo alto llc palo alto usd venezuela producto roche caracas veb share capital local currency unit annual report report group auditor report group auditor general meeting roche holding ltd basel group auditor audit consolidated financial statement income statement balance sheet statement change equity cash flow statement note page roche holding ltd year end december prior year corresponding figure audit group auditor consolidate financial statement responsibility board director responsibility express opinion consolidated financial statement base audit confirm meet legal requirement concern professional qualification independence audit conduct accordance auditing standard promulgate swiss profession international standard audit isa require audit plan perform obtain reasonable assurance consolidated financial statement free material misstatement examine test basis evidence support amount disclosure consolidated financial statement assess accounting principle significant estimate overall consolidated financial statement presentation believe audit provide reasonable basis opinion opinion consolidated financial statement true fair view financial position result operation cash flow accordance international financial reporting standard ifrs comply swiss law recommend consolidated financial statement submit approve kpmg klynveld peat marwick goerdeler john morris erik willems basel january annual report multiyear overview statistic report statement income millions chf sale ebitda operating profit net income research development balance sheet million chf longterm asset current asset total asset equity minority interest noncurrent liability current liability addition property plant equipment personnel number employee end year key ratio net income sale net income equity research development sale current ratio equity minority interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf cash warrant addition dividend adjust chf cash warrant addition dividend unadjuste chf information table state report change accounting policy arising change international financial reporting standard stock split apply retrospectively addition normal dividend shareholder approve share nonvoting equity security special centenary warrant worth chf date issue holder option cash equivalent chf net income relate key ratio show special charge million swiss franc net tax incur follow corange acquisition include corange respect balance sheet datum annual report multiyear overview warrant hold final exercise date dividend include special dividend relate spinoff fragrance flavour division dividend propose board director annual report multiyear overview sale division millions chf pharmaceutical diagnostic consumer health otc vitamin fine chemical fragrance flavour total sale geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic consumer health otc vitamin fine chemical fragrance flavour total addition property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total annual report supplementary net income ep information group basic diluted earning share information give note consolidated financial statement page supplementary eps information give net income exceptional item core net income additionally exclude amortisation intangible asset relate impact income taxis minority interest net income exceptional item core net income millions chf net income continue business goodwill amortisation income tax minority interest major legal case income tax minority interest change group organisation income tax minority interest exceptional financial income income tax minority interest net income exceptional item continue business amortisation intangible asset income tax minority interest core net income eps exceptional item core ep eps exceptional item core eps net income millions chf elimination interest expense net tax convertible debt instrument dilutive increase minority share group net income net tax assume outstanding genentech stock option exercise net income calculate diluted earning share share information million share nonvoting equity security weight average number share nonvoting equity security issue adjustment assume conversion convertible debt instrument dilutive weight average number share nonvoting equity security issue calculate diluted earning share earning share dilutedchf annual report roche security share price performance chf roche share adjust swiss market index rebase nonvoting equity security genussschein price performance chf roche nonvoting equity security adjust swiss market index rebase american depositary receipt adr price performance usd roche adr adjust index rebase roche american depositary receipt adr equivalent nonvoting equity security genussscheinadrs trade united states overthecounter market july information table restate stock split roche share nonvoting equity security genussscheine effective change ratio adrs effective january annual report roche security number share nonvoting equity securitiesa number share nominal value chf chf number nonvoting equity security genussscheine nominal value total datum share nonvoting equity security chf net income equity dividend stock price shareb high low yearend stock price nonvoting equity security genussscheinb high low yearend market capitalisation millions chf yearend key ratio yearend net income equity dividend yield share dividend yield nonvoting equity security genussscheinein priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities stock price datum reflect daily closing price dividend propose board director ticker symbol share nonvoting equity security american depositary receipt reuters ros rogvx rhhbypk bloomberg rog rhhby swx swiss exchange rog annual report roche holding ltd basel financial statement income statement millions chf income income participation interest income loan group company interest investment income gain disposal participation income group company income total income expense financial expense administration expense loss disposal participation depreciation participation expense total expense profit year taxis tax net profit year annual report financial statement balance sheet december millions chf longterm asset participation longterm loan group company total longterm asset current asset shortterm loan group company account receivable group company account receivable marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine general legal reserve free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision loan group company total noncurrent liability current liability account payable group company liabilitie total current liability total liability total equity liability pro memoria nonvoting equity security nominal value annual report note financial statement general financial statement roche holding ltd basel prepare accordance provision swiss law valuation method translation foreign currency balance sheet asset liability disclose net realisable value exception rule participation show acquisition value appropriate writedown marketable security show low cost market value unrealise foreign currency gain balance sheet item defer expense income foreign currency transaction translate exchange rate rule relevant transaction date detail specific item taxis tax charge include corporate income capital taxis withhold taxis stamp duty equity movement recognise amount millions chf general share legal free special available total capital reserve reserve reserve earnings equity january net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december share capital previous year share capital amount million swiss franc share capital consist bearer share nominal value swiss franc include equity non vote equity security genussscheine share capital confer voting right nonvoting equity security genussscheindoe confer right share participate available earning remain proceed liquidation follow repayment share capital guarantee framework european medium term note emtn programme company issue guarantee favour group company amount million swiss franc previous year million swiss franc time prepare balance sheet risk arise contingent liability discernible annual report note financial statement convertible option reference note consolidated financial statement equity instrument reference note consolidated financial statement pledge asset asset total book value million swiss franc previous year million swiss franc pledge security company commitment participation major participation list page important shareholder share company bearer share reason company register shareholder follow figure base information shareholder shareholder validation check annual general meeting april information available company previous year share shareholder group pool voting right comprise vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri mscatherine oeri beatrice oeri maja oeria previous year share participation novartis international ltd basel include affiliate thereofb information supply shareholder figure share include share pooled voting right hold outside group individual member group figure december supply novartis international ltd basel annual report appropriation available earning proposal general meeting chf available earning net profit year balance bring forward previous year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year transfer free reserve total appropriation available earning carry forward account annual report report statutory auditor general meeting roche holding ltd basel statutory auditor audit accounting record financial statement income statement balance sheet note page roche holding ltd year end december theprior year corresponding figure audit auditor financial statement responsibility board director responsibility express opinion financial statement base audit confirm meet legal requirement concern professional qualification independence audit conduct accordance auditing standard promulgate swiss profession require audit plan perform obtain reasonable assurance financial statement free material misstatement examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate overall financial statement presentation believe audit provide reasonable basis opinion opinion accounting record financial statement propose appropriation available earning comply swiss law company article incorporation recommend financial statement submit approve kpmg klynveld peat marwick goerdeler john morris erik willems basel january annual report sale manufacturing overview switzerland costa rica argentina czech republic australia denmark austria dominican republic bangladesh ecuador belgium egypt bermuda salvador brazil finland canada france chile germany china great britain colombia greece annual report roche global market presence roche global market presence research development service finance toll manufacture party guatemala morocco russia guernsey netherlands singapore honduras new zealand south africa hungary nicaragua south korea india norway spain indonesia pakistan sweden ireland panama taiwan italy peru thailand japan philippines turkey luxembourg poland uruguay malaysia portugal usa mexico puerto rico venezuela annual report publish cautionary statement forward fhoffmannla roche ltd look statement baselswitzerland annual report contain certain forwardlook tel ing statement forwardlooke statement fax identify word believe expect anticipate project intend media office seek estimate future similar expression corporate communication discussion thing strategy baselswitzerland goal plan intention factor tel cause actual result differ materially future fax reflect forwardlooke statement contain annual report investor relation pricing product initiative competitor baselswitzerland legislative regulatory development tel economic condition delay inability fax obtain regulatory approval bring prod uct market fluctuation currency world wide web exchange rate general financial market condi httpwwwrochecom tion uncertaintie discovery develop ment marketing ofnew product new use order publication exist product increase government pric tel ing pressure interruption production fax loss inability obtain adequate protec emailbaselwebmasterrochecom tion intellectual property right litigation loss ofkey executive employeesand adverse publicity news coverage annual general meeting february trademark mention enjoy legal protection roche annual report publish german original language english roche annual report issue hoffmannla roche ltd basel corporate communication design wirz corporate zurich source associates zurich photo roland tnnler zurich raphael david koch zurich roche corporate photolibrary basel typeset staufferfebel basel lithos lithoteam allschwilbasel printer birkhusergbc reinachbasel bind buchbinderei grollimund reinachbasel annual report